

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President & CEO
(Code no.: 4568, First Section of Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com>

Revision to “Reference Data (Consolidated Financial Results for FY2013)”

Tokyo, Japan (May 22, 2014) – Daiichi Sankyo Company, Limited today announced the revision below to the “Reference Data (Consolidated Financial Results for FY2013)” materials originally disclosed at 1pm on Thursday, May 15, 2014.

The file reflecting the revision below is also attached.

Revised item

Page 7, “5. Number of Employees” (before and after revised figures are underlined below)

Before Revision:


March 2014 results	
Total necessary personnel	<u>33,002</u>
Japan	9,145
Overseas	<u>23,857</u>
Daiichi Sankyo Group	<u>17,467</u>
Ranbaxy Group	15,535

After Revision:

March 2014 results	
Total necessary personnel	<u>32,791</u>
Japan	9,145
Overseas	<u>23,646</u>
Daiichi Sankyo Group	<u>17,256</u>
Ranbaxy Group	15,535

Reference Data

(Consolidated Financial Results for FY2013)



Daiichi-Sankyo

May 15, 2014

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

MEMO

(This page is intentionally left blank)

Contents

1.	Consolidated Statement of Profit or Loss	P1
2.	Segment Information	P2
3.	Revenue by Business Units	P3
4.	Revenue of Global Products	P6
5.	Number of Employees	P7
6.	Management / Financial Indicators	P8
7.	Capital Expenditure and Depreciation and Amortization	P8
8.	Consolidated Statement of Financial Position	P9
9.	Consolidated Statement of Cash Flows	P11
10.	Summary of Product Outlines	P12
11.	Major R&D Pipeline (Innovative pharmaceuticals)	P13

Supplemental Information

Historical Data

1. Summary of Consolidated Statement of Profit or Loss 【IFRS】

【JGAAP reference】

JPY Bn	FY2013				FY2014*				JPY Bn	FY2013		IFRS - JGAAP
	to revenue	Results	YoY	YoY	to revenue	Forecast	YoY	YoY		to sales	Results	
Revenue	100%	1,118.2	123.6	12.4%	100%	920.0	-198.2	-17.7%	Net sales	100%	1,118.8	-0.5
Cost of sales	36.0%	402.3	63.8	18.8%	31.0%	285.0	-117.3	-29.2%	Cost of sales	33.6%	375.5	26.8
Gross Profit	64.0%	716.0	59.8	9.1%	69.0%	635.0	-81.0	-11.3%	Gross Profit	66.4%	743.3	-27.3
SG&A expenses	36.9%	413.2	40.2	10.8%	36.2%	333.0	-80.2	-19.4%	SG&A expenses	39.1%	437.6	-24.4
R&D expenses	17.1%	191.2	6.8	3.7%	19.8%	182.0	-9.2	-4.8%	R&D expenses	17.0%	189.7	1.5
Operating Profit	10.0%	111.6	12.8	13.0%	13.0%	120.0	8.4	+7.6%	Operating Income	10.4%	115.9	-4.4
Financial income / expenses		-10.4							Non-operating income/expenses		-10.9	
<small>Share of profit or loss of investments accounted for using the equity method</small>		-1.4							Ordinary Income	9.4%	105.0	
Profit before tax	8.9%	99.8	3.9	4.1%	13.0%	120.0	20.2	+20.3%	Extraordinary income / losses		4.3	
Income taxes		46.4	16.5	55.0%					Income before income taxes and minority interests	9.8%	109.3	-9.5
Profit for the year	4.8%	53.4										
Profit attributable to owners of the Company	5.4%	60.9	-3.1	-4.8%	8.5%	78.0	17.1	+28.0%	Net Income	5.9%	65.7	-4.7
<u>Effective tax rate</u>		46.5%			*The budget for Ranbaxy group is excluded in FY2014 Plan							
<u>Overseas sales ratio results</u>		52.4%										
<u>Currency Rate</u>		<u>FY2013 Results</u>				<u>FY2014 Plan</u>						
USD／JPY		100.24				100.00						
EUR／JPY		134.38				140.00						
INR／JPY		1.68										

Notes to FY2013 YTD Results Year-on-Year Comparisons (IFRS)

Revenue	Japan company +30.5 (Nexium +32.7, Memary +9.5, Ranmark +3.6, Olmetec/Rezaltas +2.3, Mevalotin -43, Cravit -24, Calblock -20) Daiichi Sankyo Inc. +29.4 (Olmesartan +17.4, Welchol +9.1), Daiichi Sankyo Europe +19.5 (Olmesartan +17.6), ASCA company +12.6 Ranbaxy (15 months) -35.1 Currency impact (appreciation of JPY to USD and EUR +53.7, appreciation of JPY to INR +23.6)
SG&A expenses	SG&A: +40.2 (Currency impact +38.4, appreciation of JPY to USD, EUR, and INR)
R&D expenses	R&D: +6.8 (Currency impact +17.0, appreciation of JPY to USD, EUR, and INR)
Income taxes	Income taxes: +16.5 Tax rate worsened by special factors: a reversal of deferred tax assets related to a change in the tax rate following the expiration of the special corporation tax for reconstruction

Notes to FY2013 YTD Results IFRS-on-JGAAP Comparisons (reference)

Revenue	Provision for sales returns -0.5
Cost of Sales	Transfer from SG&A expenses +16.3(Amortization for Non-current assets+8.0, Royalty+8.3) Transfer from Non-operating income/expenses, Extraordinary income/losses +7.8
SG&A expenses	Transfer to Cost of Sales -16.3, Non-amortization of goodwill -7.6 Transfer from Non-operating income/expenses, Extraordinary income/losses +4.6
Operating Profit	Transfer from Non-operating income/expenses, Extraordinary income +12.6,Non-amortization of goodwill +7.6
Profit before tax	Transfer gains on sale of investment securities etc. to comprehensive income -16.4,Non-amortization of goodwill +7.6

2. Segment Information

JPY Bn

Daiichi Sankyo Group

	FY2013			
	to revenue	Results	YoY	YoY
External revenue		897.7		
Intersegment revenue		1.4		
Revenue	100%	899.1	86.2	11%
Cost of sales	31%	282.9	26.9	10%
Gross Profit	69%	616.2	59.3	11%
SG&A expenses	36%	322.7	24.6	8%
R&D expenses	20%	180.7	3.5	2%
Operating Profit	13%	112.9	31.1	38%
Financial income and expense		0.6	-0.1	
Share of profit or loss of investments accounted for using the equity method		-0.6	-0.7	
Profit before tax	13%	112.9	30.4	37%
Income taxes		47.1	26.2	
Profit for the year		65.8	4.2	
Profit attributable to owners of the Company	8%	68.8	7.4	12%

	FY2014			
	to revenue	Forecast	YoY	YoY
Revenue	100%	920.0	20.9	+2.3%
Cost of sales	31%	285.0	2.1	+0.7%
Gross Profit	69%	635.0	18.8	+3.0%
SG&A expenses	36%	333.0	10.3	+3.2%
R&D expenses	20%	182.0	1.3	+0.7%
Operating Profit	13%	120.0	7.1	+6.3%
Profit before tax	13%	120.0	7.1	+6.3%
Profit attributable to owners of the Company	8%	78.0	9.2	+13.3%

Notes to FY2014 YTD Plan Year-on-Year Comparisons

Revenue

Japan: Sales increase with major products like Memary, Nexium

Ranmark and Pralia

Overseas: Sales increase of Luitpold with Injectafer and China business

Operating Profit

Positive factors: Increase of Revenue

Decrease of SG&A expenses in US/EU

Overall cost saving in Japan

Negative factors: Cost increase relating to the launch of Edoxaban

Ranbaxy Group

External revenue		220.6		
Intersegment revenue		2.1		
Revenue	100%	222.7	37.5	20%
Cost of sales	55%	122.4	37.5	44%
Gross Profit	45%	100.3	0.0	0%
SG&A expenses	40%	89.8	17.5	24%
R&D expenses	5%	11.5	3.5	43%
Operating Profit	0%	-1.0	-20.9	-105%
Financial income and expense		-14.2	-10.9	
Share of profit or loss of investments accounted for using the equity method		-0.2	0.0	
Profit before tax	-7%	-15.4	-31.8	-194%
Income taxes		-0.8	-7.2	
Profit for the year		-14.6	-24.6	
Profit attributable to owners of the Company	-7%	-14.6	-24.4	-248%

Inter-segment Transactions

Revenue	-3.6	-0.1
Cost of sales	-3.0	-0.5
Gross Profit	-0.6	0.5
SG&A expenses	0.7	-2.0
R&D expenses	-0.9	-0.2
Operating Profit	-0.4	2.6
Financial income and expense	3.2	3.1
Share of profit or loss of investments accounted for using the equity method	-0.6	-0.4
Profit before tax	2.2	5.3
Income taxes	0.1	-2.6
Profit for the year	2.1	7.9
Profit attributable to owners of the Company	6.7	13.9

3. Revenue by Business Units

	FY2013 Plan(Jan)	Q1 Results YoY to plan	Q2 Results YoY to plan	Q3 Results YoY to plan	Q4 Results YoY to plan	FY2013* Results YoY YoY to plan	FY2014* Plan
JPY Bn							
Consolidated Revenue	1,110.0	252.5 +4.1% 23%	263.9 +9.3% 24%	290.7 +11.2% 26%	311.2 +23.4% 28%	1,118.2 123.6 +12.4% 101%	920.0
Japan Company (domestic sales)+Vaccine business	485.0	108.5 +8.7% -	117.1 +5.5% -	138.6 +11.1% -	122.3 +5.7% -	486.5 30.5 +6.7% -	508.0
Olmetec	83.0	16.6 -8.9% 20%	20.9 +8.4% 25%	22.9 +9.4% 28%	18.7 -5.9% 23%	79.1 0.8 +1.0% 95%	79.0
Rezaltas	21.0	4.3 +9.6% 21%	4.6 +12.2% 22%	5.2 +13.5% 25%	4.3 +1.0% 21%	18.5 1.5 +9.1% 88%	22.0
Calblock	9.0	2.4 -11.1% 27%	2.4 -14.5% 26%	2.3 -18.2% 26%	1.8 -30.2% 20%	8.9 -2.0 -18.3% 99%	7.0
Loxonin	61.0	14.9 +5.8% 25%	15.7 +0.6% 26%	16.2 -0.1% 27%	12.5 -9.1% 20%	59.3 -0.3 -0.6% 97%	52.0
Cravit	35.0	7.6 -5.4% 22%	8.1 -4.0% 23%	10.2 -4.4% 29%	7.6 -13.1% 22%	33.5 -2.4 -6.7% 96%	29.0
Nexium	52.0	10.9 +562.1% 21%	13.1 +375.9% 25%	16.2 +95.3% 31%	14.0 +58.1% 27%	54.2 32.7 +151.5% 104%	67.0
Memary	34.0	6.6 +28.7% 19%	7.8 +38.2% 23%	9.5 +43.9% 28%	9.5 +46.5% 28%	33.3 9.5 +40.0% 98%	50.0
Mevalotin	22.0	5.2 -20.5% 24%	5.9 -12.5% 27%	5.9 -10.0% 27%	4.5 -24.9% 20%	21.5 -4.3 -16.8% 98%	17.0
Artist	22.0	5.4 -3.4% 25%	5.7 +0.6% 26%	6.0 +3.6% 28%	5.3 -0.9% 24%	22.4 0.0 +0.0% 102%	21.0
Omnipaque	19.0	4.7 -4.0% 25%	5.2 -0.7% 28%	5.6 +4.3% 29%	4.1 -10.7% 22%	19.7 -0.5 -2.5% 104%	15.0
Urief	12.0	2.7 +0.1% 22%	2.9 +4.2% 24%	3.2 +9.4% 27%	2.6 -2.1% 22%	11.4 0.3 +3.1% 95%	10.0
Inavir	10.0	0.3 -38.8% 3%	0.0 -90.6% 0%	1.8 -15.2% 18%	11.4 +33.3% 114%	13.4 2.3 +20.8% 135%	10.0
Ranmark	7.0	1.6 +162.8% 22%	1.9 +68.0% 27%	2.4 +76.8% 34%	2.3 +64.2% 32%	8.1 3.6 +82.2% 115%	10.0
Pralia	not disclosed	0.4 - -	0.6 - -	0.8 - -	1.5 - -	3.2 3.2 - -	12.0
Daiichi Sankyo Espha products	not disclosed	2.9 +3.6% -	3.0 +13.2% -	3.8 +27.3% -	2.7 +4.5% -	12.5 1.4 +12.5% -	not disclosed
Vaccines business	not disclosed	9.3 +64.2% -	8.3 -26.3% -	13.9 -8.6% -	6.1 -13.8% -	37.5 -1.6 -4.2% -	not disclosed
Daiichi Sankyo Healthcare (OTC)	48.0	9.8 -4.6% 20%	13.1 +2.5% 27%	14.1 -2.8% 29%	11.0 +16.1% 23%	48.1 1.0 +2.1% 100%	48.0
Daiichi Sankyo, Inc. (US)	163.0	46.6 +29.7% 29%	39.9 +22.2% 25%	44.6 +19.3% 27%	40.7 +11.9% 25%	171.8 29.4 +20.7% 105%	164.0
Olmesartan	103.0	30.7 +28.4% 30%	26.1 +20.0% 25%	28.7 +11.8% 28%	26.8 +13.6% 26%	112.3 17.4 +18.3% 109%	105.0
Benicar/Benicar HCT	79.0	23.8 +26.1% 30%	20.2 +20.6% 26%	21.6 +7.0% 27%	20.3 +16.3% 26%	85.9 12.6 +17.2% 109%	77.0
Azor	15.0	4.6 +31.6% 31%	3.8 +9.3% 25%	4.4 +15.6% 29%	4.6 +13.6% 31%	17.4 2.6 +17.4% 116%	17.0
Tribenzor	8.0	2.3 +49.3% 29%	2.1 +39.1% 26%	2.7 +62.6% 33%	1.9 -8.5% 24%	9.0 2.2 +32.3% 113%	9.0
Welchol	43.0	11.4 +37.4% 26%	9.6 +33.8% 22%	11.7 +39.8% 27%	9.6 +3.2% 22%	42.3 9.1 +27.6% 98%	41.0
Effient (alliance revenue)	not disclosed	4.0 +65.0% -	3.6 +55.1% -	3.8 +38.8% -	4.0 +32.6% -	15.4 4.9 +46.7% -	not disclosed
Luitpold Pharmaceuticals, Inc. (US)	40.0	8.1 -28.7% 20%	10.2 +32.0% 25%	9.6 -15.6% 24%	11.8 +43.6% 30%	39.6 1.0 +2.6% 99%	50.0
Venofer	26.0	4.9 -27.7% 19%	6.8 +76.5% 26%	6.4 -23.0% 25%	6.8 +45.7% 26%	24.9 1.3 +5.4% 96%	19.0
Injectafer	not disclosed	- - -	0.2 - -	0.3 - -	0.8 - -	1.3 1.3 - -	10.0
Daiichi Sankyo Europe GmbH	78.0	19.0 +36.8% 24%	21.4 +41.8% 27%	23.3 +37.6% 30%	20.2 +9.3% 26%	83.9 19.5 +30.3% 108%	81.0
Olmesartan	60.0	14.4 +45.0% 24%	16.8 +48.0% 28%	18.7 +44.7% 31%	15.8 +14.0% 26%	65.6 17.6 +36.7% 109%	63.0
Olmetec/Olmetec Plus	41.0	9.8 +52.4% 24%	11.6 +42.6% 28%	12.7 +47.8% 31%	10.5 +10.7% 26%	44.5 11.9 +36.7% 109%	36.0
Sevikar	12.0	3.0 +19.5% 25%	3.1 +32.6% 26%	4.0 +30.2% 33%	3.4 +19.5% 29%	13.5 2.7 +25.3% 112%	16.0
Sevikar HCT	6.0	1.6 +62.2% 26%	2.1 +136.2% 35%	2.0 +58.8% 34%	1.9 +23.6% 32%	7.6 2.9 +62.9% 127%	9.0
Effient (alliance revenue)	not disclosed	1.2 +30.3% -	1.1 +23.1% -	1.2 +32.5% -	1.2 +1.2% -	4.7 - +20.5% -	not disclosed

Currency rate YoY comparison		Q1 Results			Q2 YTD Results			Q3 YTD Results			Q4 YTD Results			FY2014 Plan	
		USD	EUR	INR	USD	EUR	INR	USD	EUR	INR	USD	EUR	INR	USD	EUR
	FY2012	80.21	102.91	1.59	79.42	100.64	1.54	80.01	102.18	1.50	83.11	107.15	1.50		
	FY2013	98.76	128.96	1.71	98.86	130.01	1.74	99.39	132.24	1.69	100.24	134.38	1.68	100.00	140.00
	YoY	18.55	26.05	0.12	19.44	29.37	0.20	19.38	30.06	0.19	17.13	27.23	0.18		
Currency rate impact (Bn yen)		Revenue			Operating Profit			Revenue			Operating Profit				
		about +18.0 Bn yen			about +0.5 Bn yen			about +41.0 Bn yen			about +1.0 Bn yen				
		about +18.0 Bn yen			about +0.5 Bn yen			about +61.0 Bn yen			about +4.0 Bn yen				
		about +18.0 Bn yen			about +0.5 Bn yen			about +61.0 Bn yen			about +4.0 Bn yen				
Currency rate sensitivity (Bn yen)		Annual impact of one yen change is estimated to affect the group's FY2014 performance by; USD: revenue 2.2 bil yen, operating profit minor / EUR: revenue 0.6 bil yen, operating profit minor													

3. Revenue by Business Units

	FY2013 Plan(Jan)	Q1			Q2			Q3			Q4			FY2013*				FY2014* Plan
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan	
JPY Bn																		
Asia, South and Central America (ASCA)	46.0	12.7	+49.0%	-	14.1	+50.8%	-	15.0	+55.8%	-	16.9	-9.5%	-	58.8	12.6	+27.3%	-	59.0
Daiichi Sankyo China	not disclosed	4.7	+77.3%	-	4.9	+62.6%	-	5.3	+71.4%	-	6.3	-18.1%	-	21.2	4.8	+29.2%	-	not disclosed
Daiichi Sankyo Taiwan	not disclosed	1.1	+40.0%	-	1.1	+37.5%	-	1.1	+37.6%	-	1.2	+28.4%	-	4.5	1.2	+35.6%	-	not disclosed
Daiichi Sankyo Korea	not disclosed	1.8	+44.6%	-	2.2	+79.1%	-	2.7	+102.1%	-	2.4	+55.3%	-	9.1	3.7	+69.8%	-	not disclosed
Daiichi Sankyo (Thailand)	not disclosed	0.4	+46.7%	-	0.4	+36.5%	-	0.8	+107.1%	-	0.9	+112.9%	-	2.5	1.1	+81.4%	-	not disclosed
Daiichi Sankyo Brasil Farmacêutica	not disclosed	1.7	+40.8%	-	2.0	+72.5%	-	2.0	+100.5%	-	1.8	-44.5%	-	7.5	0.9	+13.8%	-	not disclosed
Daiichi Sankyo Venezuela	not disclosed	1.3	+48.4%	-	1.8	+22.7%	-	1.5	-1.5%	-	2.4	-18.4%	-	6.9	0.2	+2.7%	-	not disclosed
Ranbaxy Group**	224.0	42.3	-28.4%	-	45.7	-4.1%	-	44.5	+16.0%	-	88.1	+118.4%	-	220.6	35.1	+19.0%	-	
Others	26.0	5.5	-20.3%	-	2.4	-77.7%	-	1.1	-89.2%	-	0.1	-100.6%	-	9.0	-5.5	-73.4%	-	

* Of revenues included in "Others", revenues of "Export, royalty to US/EU region" is transferred to Japan Company, revenues of "Licensee business in ASCA region" is transferred to ASCA Company, revenues of "Vaccine business" is transferred to "Vaccine business" under Japan Company, respectively.

** Since Ranbaxy Group has changed their fiscal year-end from December to March, their FY2013 financial results is for 15 months. 6 months results from 2013 Oct. to 2014 March are shown in Q4 results.

[Reference] Revenue in Local Currency

	FY2013 Plan(Jan)	Q1 Results YoY to plan			Q2 Results YoY to plan			Q3 Results YoY to plan			Q4 Results YoY to plan			FY2013 Results YoY YoY to plan				FY2014 Plan
USD Mn																		
Daiichi Sankyo, Inc. (US)	1,682	472	+5.3%	28%	403.0	-3.0%	24%	444.0	-3.6%	26%	395.0	+1.7%	24%	1,714	1	+0.1%	102%	1,640
Olmesartan	1,063	311	+4.3%	29%	263	-4.7%	25%	286	-9.7%	27%	260	+3.8%	25%	1,120	-22	-1.9%	105%	1,050
Benicar/Benicar HCT	815	241	+2.4%	30%	204	-4.3%	25%	215	-13.7%	26%	197	+7.1%	24%	857	-25	-2.8%	105%	770
Azor	155	47	+6.9%	30%	38	-13.2%	25%	44	-6.6%	28%	45	+2.5%	29%	174	-5	-2.7%	112%	170
Tribenzor	83	23	+21.3%	28%	21	+10.5%	26%	26	+31.6%	32%	19	-19.6%	23%	90	8	+9.7%	109%	90
Welchol	444	115	+11.6%	26%	97	+6.2%	22%	116	+13.0%	26%	93	-7.8%	21%	422	23	+5.8%	95%	410
Effient (alliance revenue)	not disclosed	41	+34.0%	-	37	+23.2%	-	38	+12.0%	-	39	+18.7%	-	154	27	+21.6%	-	not disclosed
USD Mn																		
Luitpold Pharmaceuticals, Inc. (US)	413	82	-42.1%	20%	103.0	+4.4%	25%	95.0	-31.9%	23%	115.0	+36.2%	28%	395	-69	-14.9%	96%	500
Venofer	268	50	-41.2%	19%	68	+39.2%	26%	64	-38.0%	24%	66	+40.2%	25%	248	-36	-12.6%	93%	190
Injectafer	not disclosed	0	-	-	2	-	-	3	-	-	7	-	-	13	-	-	-	100
EUR Mn																		
Daiichi Sankyo Europe GmbH	600	147	+9.2%	25%	163.0	+6.8%	27%	171.0	+6.0%	29%	143.0	-6.0%	24%	624	23	+3.9%	104%	579
Olmesartan	462	111	+15.7%	24%	128	+11.6%	28%	137	+11.4%	30%	112	-2.0%	24%	488	40	+9.0%	106%	450
Olmetec/Olmetec Plus	315	76	+21.6%	24%	89	+7.7%	28%	93	+13.9%	30%	74	-5.1%	23%	331	27	+9.0%	105%	257
Sevikar	92	23	-4.6%	25%	23	-0.5%	25%	29	+0.4%	32%	24	+4.7%	27%	100	-0	-0.1%	109%	114
Sevikar HCT	46	12	+29.4%	27%	16	+77.5%	35%	15	+21.6%	32%	13	+4.1%	29%	57	13	+29.9%	123%	64
Efient (alliance revenue)	not disclosed	9	+4.0%	-	8	-7.5%	-	9	+2.2%	-	8	-13.2%	-	35	-1	-3.9%	-	not disclosed
INR Bn																		
Ranbaxy Group*	135	25	-33.5%	-	26.0	-19.7%	-	28.0	+1.5%	-	53.0	+96.7%	-	131	30	+6.2%	-	

* Since Ranbaxy Group has changed their fiscal year-end from December to March, their FY2013 financial results is for 15 months. 6 months results from 2013 Oct. to 2014 March are shown in Q4 results.

4. Revenue of Global Products

	FY2013 Plan(Jan)	Q1			Q2			Q3			Q4			FY2013				FY2014 Plan
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan	
JPY Bn																		
Olmesartan	289.0	71.4	+19.0%	25%	74.6	+22.7%	26%	81.9	+19.8%	28%	72.3	+3.7%	25%	300.2	41.3	+16.0%	104%	289.0
Olmetec (JPN)	83.0	16.6	-8.9%	20%	20.9	+8.4%	25%	22.9	+9.4%	28%	18.7	-5.9%	23%	79.1	0.8	+1.0%	95%	79.0
Rezaltas (JPN)	21.0	4.3	+9.6%	21%	4.6	+12.2%	22%	5.2	+13.5%	25%	4.3	+1.0%	21%	18.5	1.5	+9.1%	88%	22.0
Benicar/Benicar HCT (US)	79.0	23.8	+26.1%	30%	20.2	+20.6%	26%	21.6	+7.0%	27%	20.3	+16.3%	26%	85.9	12.6	+17.2%	109%	77.0
Azor (US)	15.0	4.6	+31.6%	31%	3.8	+9.3%	25%	4.4	+15.6%	29%	4.6	+13.6%	31%	17.4	2.6	+17.4%	116%	17.0
Tribenzor (US)	8.0	2.3	+49.3%	29%	2.1	+39.1%	26%	2.7	+62.6%	33%	1.9	-8.5%	24%	9.0	2.2	+32.3%	113%	9.0
Olmetec/Olmetec Plus (EU)	41.0	9.8	+52.4%	24%	11.6	+42.6%	28%	12.7	+47.8%	31%	10.5	+10.7%	26%	44.5	11.9	+36.7%	109%	36.0
Sevikar (EU)	12.0	3.0	+19.5%	25%	3.1	+32.6%	26%	4.0	+30.2%	33%	3.4	+19.5%	29%	13.5	2.7	+25.3%	112%	16.0
Sevikar HCT (EU)	6.0	1.6	+62.2%	26%	2.1	+136.2%	35%	2.0	+58.8%	34%	1.9	+23.6%	32%	7.6	2.9	+62.9%	127%	9.0
Other subsidiaries, export, etc	24.0	5.4	+35.4%	23%	6.2	+44.0%	26%	6.5	+49.9%	27%	6.7	-18.0%	28%	24.7	4.0	+19.2%	103%	24.0
Prasugrel	not disclosed	5.2	+55.6%	-	4.7	+46.3%	-	5.0	+37.2%	-	5.2	+24.0%	-	20.1	5.7	+39.6%	-	not disclosed
Effient alliance revenue (US)	not disclosed	4.0	+65.0%	-	3.6	+55.1%	-	3.8	+38.8%	-	4.0	+32.6%	-	15.4	4.9	+46.7%	-	not disclosed
Efient alliance revenue (EU)	not disclosed	1.2	+30.3%	-	1.1	+23.1%	-	1.2	+32.5%	-	1.2	+1.2%	-	4.7	0.8	+20.5%	-	not disclosed

5. Number of Employees

	Mar 2013 Results	Jun 2013 Results	Sep 2013 Results	Dec 2013 Results	Mar 2014 Results
Total Number of Employees	32,229	32,402	32,193	32,001	32,791
Japan	9,251	9,379	9,317	9,302	9,145
Overseas	22,978	23,023	22,876	22,699	23,646
Daiichi Sankyo Group	17,528	17,716	17,549	17,451	17,256
Ranbaxy Group	14,701	14,686	14,644	14,550	15,535

6. Management / Financial Indicators

	FY2012 Results	FY2013 Results	FY2014 Forecast
Management Indicators			
Basic earnings per share	91.0 Yen	86.6 Yen	110.8 Yen
Dividend per share	60.0 Yen	60.0 Yen	60.0 Yen
Dividend payout ratio (Consolidated)	66.0 %	69.3 %	54.2 %
Return on equity attributable to owners of the Company	7.4 %	6.5 %	
Ratio of dividends to equity attributable to owners of the Company	4.9 %	4.5 %	
Equity per share attributable to owners of the Company	1,287.9 Yen	1,392.0 Yen	
Ratio of equity attributable to owners of the Company to total assets	53.8 %	52.9 %	
Total number of common shares	704 million	704 million	
Share price at end of period	1,815 Yen	1,738 Yen	
Market value	1,277.7 JPY Bn	1,223.5 JPY Bn	
Financial Indicators			
Total assets	1,684.9 JPY Bn	1,854.0 JPY Bn	
Current assets	829.8 JPY Bn	990.6 JPY Bn	
*1 Liquidity on hand	374.9 JPY Bn	507.3 JPY Bn	
Debt with interest	270.1 JPY Bn	426.8 JPY Bn	
Net Cash	104.8 JPY Bn	80.5 JPY Bn	
Equity capital	906.6 JPY Bn	979.9 JPY Bn	
Cash flows from operating activities	129.3 JPY Bn	37.3 JPY Bn	
Cash flows from investing activities	-108.8 JPY Bn	-161.4 JPY Bn	
Cash flows from financial activities	-58.2 JPY Bn	100.3 JPY Bn	
*2 Free cash flows	20.4 JPY Bn	-124.1 JPY Bn	
Cash and cash equivalents at the end of the year	191.1 JPY Bn	183.1 JPY Bn	
Others			
Number of consolidated subsidiaries	104	96	

*1 Current deposits + marketable securities + investment securities, etc

*2 Cash flows from operating activities and investing activities

7. Capital Expenditure and Depreciation and Amortization

	FY2012 Results	FY2013 Results	FY2014 Plan*
Capital expenditure	65.1 JPY Bn	49.2 JPY Bn	38.0 JPY Bn
Depreciation and amortization	41.4 JPY Bn	51.5 JPY Bn	39.0 JPY Bn
Property, plant and equipment	25.6 JPY Bn	30.5 JPY Bn	
Intangible assets	15.8 JPY Bn	21.0 JPY Bn	

*The budget for Ranbaxy group is excluded in FY2014 Plan

8. Consolidated Statement of Financial Position

(Billions of yen)

	Mar 2013	Mar 2014	YoY	Notes
Assets				
Current assets				
Cash and cash equivalents	191.1	183.1	-8.1	
Trade and other receivables	262.9	269.2	6.3	
Other financial assets	182.4	324.2	141.8	
Inventories	173.8	189.4	15.6	
Other current assets	19.6	24.8	5.2	
Total current assets	829.8	990.6	160.8	
Non-current assets				
Property, plant and equipment	290.6	316.3	25.7	Newly added: Daiichi Sankyo +17.9 Bn
Goodwill	84.7	85.5	0.8	
Intangible assets	171.1	171.4	0.3	
Investments accounted for using the equity method	4.8	2.6	-2.2	
Other financial assets	145.1	141.6	-3.6	
Deferred tax assets	142.0	122.6	-19.4	
Other non-current assets	16.8	23.5	6.7	
Total non-current assets	855.2	863.4	8.3	
Total assets	1,684.9	1,854.0	169.1	

(Billions of yen)

	Mar 2013	Mar 2014	YoY	Notes
Liabilities and equity				
Current liabilities				
Trade and other payables	225.9	245.4	19.5	
Bonds and borrowings	66.1	160.3	94.3	Daiichi Sankyo +70.0 Bn (Transfer from non-current liabilities +90.0 Bn, Payment -20.0 Bn)
Other financial liabilities	9.5	15.1	5.6	
Income taxes payable	23.0	5.6	-17.4	
Provisions	59.9	22.7	-37.2	Payment of provision for settlement expenses -43.7 Bn
Other current liabilities	40.2	12.0	-28.2	
Total current liabilities	424.6	461.2	36.6	
Non-current liabilities				
Bonds and borrowings	200.7	263.3	62.5	Daiichi Sankyo +51.0 Bn (Issuance and loan +141.0 Bn, Transfer to current liabilities -90.0 Bn)
Other financial liabilities	23.6	14.2	-9.4	
Post employment benefit liabilities	31.3	8.9	-22.3	
Provisions	1.4	3.7	2.4	
Deferred tax liabilities	38.7	39.8	1.1	
Other non-current liabilities	26.2	55.3	29.2	
Total non-current liabilities	321.9	385.3	63.4	
Total liabilities	746.5	846.5	100.0	
Equity				
Equity attributable to owners of the Company				
Share capital	50.0	50.0	0.0	
Capital surplus	105.2	105.3	0.1	
Treasury shares	-14.5	-14.4	0.1	
Other components of equity	85.1	121.8	36.7	Increase in exchange differences on translation of foreign operations +39.7 Bn
Retained earnings	680.8	717.3	36.5	Profit for the year(owners of the Company) +60.9 Bn, Transfer from other components of equity +17.7 Bn, Dividends -42.2 Bn
Total equity attributable to owners of the Company	906.6	979.9	73.3	
Non-controlling interests				
Non-controlling interests	31.8	27.6	-4.2	
Total equity	938.5	1,007.5	69.0	
Total liabilities and equity	1,684.9	1,854.0	169.1	

9. Consolidated Statement of Cash Flows

(Billions of yen)

	FY2012 Results	FY2013 Results	YoY	Notes
Cash flows from operating activities				
Profit before tax	95.9	99.8	3.9	
Depreciation and amortization	45.3	51.5	6.2	
(Increase) decrease in receivables and payables	-11.0	6.1	17.1	
Other, net	22.7	-65.2	-87.9	FY2013: Ranbaxy payment for settlement expenses (-49.8)
Income taxes paid	-23.5	-54.8	-31.3	
Net cash flows from operating activities	129.3	37.3	-92.0	
Cash flows from investing activities				
Net (increase) decrease in time deposits and securities	-57.2	-120.1	-62.9	
(Acquisition of) proceeds from sales of fixed assets	-77.0	-42.6	34.4	
Other, net	25.3	1.3	-24.0	
Net cash flows from investing activities	-108.8	-161.4	-52.5	
Cash flows from financing activities				
Proceeds from bonds and borrowings	27.1	194.1	167.0	
Repayments of bonds and borrowings	-42.2	-50.5	-8.3	
Dividends paid	-42.2	-42.2	0.0	
Other, net	-0.9	-1.1	-0.2	
Net cash flows from financing activities	-58.2	100.3	158.6	
Net increase (decrease) in cash and cash equivalents	-37.8	-23.7	14.0	
Cash and cash equivalents at the beginning of the year	212.9	191.1	-21.8	
Effect of exchange rate changes on cash and cash equivalents	16.0	15.7	-0.3	
Cash and cash equivalents at the end of the year	191.1	183.1	-8.1	

10. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance
Japan Company (domestic sales)					
Olmetec	olmesartan	antihypertensive	2004	Daiichi Sankyo	
Rezaltas	olmesartan / azelnidipine	antihypertensive	2010	Daiichi Sankyo	
Calblock	azelnidipine	antihypertensive	2003	Ube Industries	
Loxonin			1986	Daiichi Sankyo	
Loxonin Poultice			2006	Lead Chemical	
Loxonin Tape	loxoprofen	analgesic and anti-inflammatory	2008	Lead Chemical	
Loxonin Gel			2010	Daiichi Sankyo	
Cravit	levofloxacin	antibacterial	1993	Daiichi Sankyo	
Nexium	esomeprazole	proton pump inhibitor	2011	AstraZeneca	AstraZeneca
Memary	memantine	treatment for Alzheimer's Disease	2011	Merz	
Mevalotin	pravastatin	antihyperlipidemic	1989	Daiichi Sankyo	
Artist	carvedilol	antihypertensive	1993	Roche	
Omnipaque	iohexol	contrast medium	1987	GE Healthcare	
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei
Inavir	laninamivir	anti-influenza	2010	Daiichi Sankyo	
Ranmark	denosumab	anti-RANKL antibody	2012	Amgen	AstraZeneca
Pralia	denosumab	anti-RANKL antibody	2013	Amgen	
Daiichi Sankyo, Inc. (US)					
Olmesartan					
Benicar	olmesartan		2002		
Benicar HCT	olmesartan / hydrochlorothiazide	antihypertensive	2003	Daiichi Sankyo	
Azor	olmesartan / amlodipine		2007		
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010		
Welchol	colesevelam	antihyperlipidemic / type 2 diabetes	2000	Genzyme	
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly
Luitpold Pharmaceuticals, Inc. (US)					
Venofer	iron sucrose injection	iron deficiency anemia	2000	Vifor Pharma	Fresenius
Injectafer	ferric carboxymaltose injection	iron deficiency anemia	2013	Vifor Pharma	
Daiichi Sankyo Europe GmbH					
Olmesartan					
Olmetec	olmesartan		2002		
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive	2005	Daiichi Sankyo	Menarini
Sevikar	olmesartan / amlodipine		2009		Pfizer
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010		Nycomed
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly

11. Major R&D Pipeline (Innovative pharmaceuticals)

As of May, 2014

◆ Launched/Approved

Generic Name	Class	Target indication	Stage	Remarks
Denosumab	Anti-RANKL antibody	Osteoporosis	JP	Launched Jun 2013
The fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation. Launched in Japan in April 2012 as treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors, and in June 2013 as treatment for osteoporosis.				
Laninamivir	Neuraminidase inhibitor	Anti-influenza, prophylactic	JP	Approved/ Launched Dec 2013
The long-acting neuraminidase inhibitor developed and produced by Daiichi Sankyo. This is an inhalant that will act directly on the pulmonary and tracheal sites of infection. Launched in Japan in October 2010 as treatment for influenza A and influenza B viruses.				
Prasugrel	Anti-platelet agent	Ischemic heart disease undergoing PCI	JP	Approved Mar 2014
The oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Ltd. Prasugrel helps keep blood platelets from clumping together and developing a blockage in an artery				

◆ Filed

Generic Name	Class	Target indication	Stage	Remarks
Denosumab	Anti-RANKL antibody	Giant cell tumor of bone	JP	Filed Aug 2013
Application to manufacture and market RANMARK®. Denosumab obtained orphan drug designation for GCTB indication in June 2013				
Edoxaban	Factor Xa inhibitor	Atrial Fibrillation (AF)	JP/US/EU	Filed Dec 2013(JP) Jan 2014(US/EU)
		Venous thromboembolism (VTE)	JP/US/EU	Filed Dec 2013(JP) Jan 2014(US/EU)
The once daily oral anti coagulant (FXa inhibitor) doscovered by Daiichi Sankyo.Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Launched in Japan in July 2011 as the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery.				

◆ Under development (Phase1-3)

Generic Name / Project code number	Class	Target indication	Stage		Remarks
Prasugrel	Anti-platelet agent	Ischemic stroke	JP	P3	
		Sickle cell disease	US	P3	
Denosumab	Anti-RANKL antibody	Breast cancer adjuvant	JP	P3	
		Rheumatoid arthritis	JP	P3	
Levofloxacin	New quinolone	Infection disease	JP	P3	
Tivantinib	MET inhibitor	Hepatocellular cancer	US/EU	P3	
Nimotuzumab	Anti-EGFR antibody	Gastric cancer	JP	P3	
		Esophageal cancer	JP	P1	
Hydromorphone	opioid mu-receptor agonist	Cancer pain	JP	P3	
CS-3150	MR antagonist	Hypertension	JP	P2	
		Diabetic nephropathy	JP	P2	
Patritumab	Anti-HER3 antibody	Non small cell lung cancer	US/EU	P2	
		Non small cell lung cancer	JP	P1	
		Breast cancer	US	P2	
		Breast cancer	JP	P1	
Vemurafenib	BRAF inhibitor	Colorectal cancer	US/EU	P2	
PLX3397	Fms/Kit/Flt3-ITD inhibitor	Acute myeloid leukemia	US	P2	
		Glioblastoma	US	P2	
		Melanoma	US	P2	
		Pigmented villonodular synovitis	US	P1	
Mirogabalin	$\alpha 2\delta$ ligand	Chronic pain	Global	P2	
SUN13837	Modulator of bFGF signaling system	Spinal cord injury	US/EU	P2	
GE-145	X-ray contrast media	Angiography	JP	P2	
Laninamivir	Neuraminidase inhibitor	Influenza	US/EU	P2	
DS-7309	Glucokinase activator	Diabetes	-	P1	
DS-8500	GPR119 agonist	Diabetes	-	P1	
DS-1442	CETP inhibitor	Dyslipidemia	-	P1	
DS-1040	TAFla inhibitor	Acute ischemic stroke	-	P1	
U3-1565	Anti-HB-EGF antibody	Solid cancer	US/JP	P1	
DS-2248	HSP90 inhibitor	Solid cancer	US	P1	
DS-7423	PI3K/mTOR inhibitor	Solid cancer	US/JP	P1	

◆ Under development (Phase1-3)

Generic Name / Project code number	Class	Target indication	Stage		Remarks
DS-3078	mTOR inhibitor	Solid cancer, lymphoma	US/EU	P1	
DS-3032	MDM2 inhibitor	Solid cancer, lymphoma	US	P1	
PLX7486	Fms/Trk inhibitor	Solid cancer	US	P1	
DS-8895	Anti-EPHA2 antibody	Solid cancer	JP	P1	
DS-8273	Anti-DR5 antibody	Solid cancer	US	P1	
PLX8394	BRAF inhibitor	Solid cancer, leukemia	US	P1	
PLX5622	FMS kinase inhibitor	Rheumatoid arthritis	-	P1	
DS-1093	HIF-PH inhibitor	Anemia of chronic kidney disease	-	P1	
DS-3801	GPR 38 agonist	Chronic obstipation	-	P1	
DS-1971	Pain	Chronic pain	-	P1	

◆ Change of stage from announcement in Oct 2013

Generic Name / Project code number	Class	Target indication	Stage	
GE-145	X-ray contrast media	Angiography	JP	P2
PLX3397	Fms/Kit/Flt3-ITD inhibitor	Melanoma	US	P2
		Pigmented villonodular synovitis	US	P1
DS-8273	Anti-DR5 antibody	Solid cancer	US	P1
PLX8394	BRAF inhibitor	Solid cancer, leukemia	US	P1
DS-3801	GPR 38 agonist	Chronic obstipation	-	P1
DS-1971	Pain	Chronic pain	-	P1

◆ Discontinue

Generic Name / Project code number	Class	Target indication	Stage	
Nimotuzumab	Anti-EGFR antibody	Non small cell lung cancer	JP	P3
< Reason for discontinuation>				
Daiichi Sankyo decided to discontinue this study based on the recent recommendation of the Independent Data Monitoring Committee.				
Vemurafenib	BRAF inhibitor	Thyroid cancer	US/EU	P2
< Reason for discontinuation>				
Removed from Phase II. Roche has deferred further development of vemurafenib in thyroid cancer.				
PLX3397	Fms/Kit/Flt3-ITD inhibitor	Prostate Cancer/Hodgkin Lymphoma	US	P2
< Reason for discontinuation>				
Daiichi Sankyo decided to discontinue the development of PLX3397 in these target indications after reviewing its clinical study result.				
ASB17061	Chymase inhibitor	Atopic Dermatitis	US	P2
< Reason for discontinuation>				
Daiichi Sankyo decided to discontinue the development of ASB17061 after reviewing its clinical study result.				
CS-0777	S1P receptor modulator	Immunomodulator	-	P1
< Reason for the in-house discontinuation>				
Daiichi Sankyo decided not to develop this compound by ourselves in order to concentratate management resources on promising business areas.				
CS-4771	TLR4 inhibitor	Sepsis	-	P1
< Reason for the in-house discontinuation>				
Daiichi Sankyo decided not to develop this compound by ourselves in order to concentratate management resources on promising business areas.				
DS-8587	Topoisomerase inhibitor	Bacterial infection	-	P1
< Reason for discontinuation>				
Daiichi Sankyo decided to discontinue the development of DS-8587 after reviewing its clinical study result.				

◆ Major R&D Pipeline Table

As of May, 2014

Therapeutic Area	Phase1	Phase2	Phase3	Application
Cardiovascular - Metabolics	DS-7309 (Diabetes / Glucokinase activator) DS-8500 (Diabetes / GPR119 agonist) DS-1442 (Dyslipidemia / CETP inhibitor) DS-1040 (Acute ischemic stroke / TAFIa inhibitor)	CS-3150 (JP) (Hypertension / Diabetic nephropathy// MR antagonist)	Prasugrel (JP) (CS-747 / ischemic stroke / anti-platelet agent) Prasugrel (US) (CS-747 / sickle cell disease / anti-platelet agent)	Prasugrel (JP) (CS-747 / PCI / anti-platelet agent) Edoxaban (Global) (DU-176b / AF / oral factor Xa inhibitor) Edoxaban (Global) (DU-176b / VTE / oral factor Xa inhibitor)
Oncology	U3-1565 (US/JP) (Anti-HB-EGF antibody) DS-2248 (US) (HSP90 inhibitor) DS-7423 (US/JP) (PI3K/mTOR inhibitor) DS-3078 (US/EU) (mTOR inhibitor) DS-3032 (US) (MDM2 inhibitor) PLX7486 (US) (Fms/Trk inhibitor) DS-8895 (JP) (Anti-EPHA2 antibody) DS-8273 (US) (Anti-DR5 antibody) PLX8394 (US) (BRAF inhibitor)	Patritumab (US/EU) (U3-1287 / anti-HER3 antibody) Vemurafenib (US/EU) (PLX4032 / BRAF inhibitor) PLX3397 (US) (Fms/Kit/Flt3-ITD inhibitor)	Tivantinib (US/EU) (ARQ 197 / HCC / MET inhibitor) Denosumab (JP) (AMG 162 / breast cancer adjuvant / anti-RANKL antibody) Nimotuzumab (JP) (DE-766 / NSCLC / anti-EGFR antibody) Nimotuzumab (JP) (DE-766 /Gastric cancer / anti-EGFR antibody)	Denosumab (JP) (AMG 162 / Giant cell tumor / anti-RANKL antibody)
Others	DS-8587 (Anti-bacterial / Topoisomerase inhibitor) CS-4774 (Anti-sepsis / TLR4 inhibitor) PLX5622 (Rheumatoid arthritis / FMS kinase inhibitor) CS-0777 (Immunomodulator / S4P receptor modulator) DS-1093 (Anemia of chronic kidney disease/HIF-PH inhibitor) DS-3801 (Chronic obstipation/GPR 38 agonist) DS-1971 (Chronic pain)	Mirogabalin (Global) (DS-5565 / Chronic pain / α2δ ligand) SUN13837 (US/EU) (Spinal cord injury / Modulator of bFGF signaling system) ASB17061 (US) (Atopic Dermatitis / chymase inhibitor) Laninamivir (US/EU) (CS-8958 / anti-influenza / Outlicensing with Biota) Ioforminol (GE-145 / X-ray contrast media/Angiography)	Denosumab (JP) (AMG 162 / Rheumatoid arthritis / anti-RANKL antibody) Levofloxacin (JP) (DR-3355 / anti-infection / New quinolone) Hydromorphone (JP) (DS-7113 / Cancer pain/ opioid mu-receptor agonist)	

Cardiovascular-Metabolics

[Project after Phase 2]

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Edoxaban	DU-176b	Oral	Factor Xa inhibitor	Atrial fibrillation (AF) Venous thromboembolism (VTE)	Daiichi Sankyo	Lixiana(JP) LIXIANA(EU, Planned) SAVAYSA(US, Planned)

<Summary>
 The once daily oral anti coagulant (FXa inhibitor). Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Launched in Japan in July 2011 as the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery.

- [JP] Launched for the prevention of VTE after major orthopedic surgery in July-2011. Brand name: Lixiana
- Hokusai-VTE(VTE) P3 studies was presented at ESC 2013.
- ENGAGE AF-TIMI 48(AF) P3 study was presented at AHA 2013.
- NDA for AF/VTE indication Filed. (JPN: Dec, 2013, US/EU: Jan, 2014)

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Prasugrel	CS-747	Oral	Anti-platelet agent	Ischemic stroke Sickle cell disease	Daiichi Sankyo Ube Industries	Effient (US, Asia) Efient (JPN, EU)

<Summary>
 The oral antiplatelet agent. Prasugrel helps keep blood platelets from clumping together and developing a blockage in an artery

- Co-development with Eli Lilly in the US and EU, development by Daiichi Sankyo in Japan.
- [JP] Approved in Mar-2014 for the ischemic heart disease undergoing PCI. P3 studies for ischemic stroke are on-going.
The Ph3 studies completion will be determined based on accumulation of ischemic events as endpoint.
- [US] P3 study in pediatric sickle cell disease patients is on-going.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	CS-3150	Oral	MR antagonist	Hypertension Diabetic nephropathy	Exelixis	TBD

<Summary>
 The agent inhibits aldosterone binding to Mineralocorticoid Receptor(MR) which stimulate the sodium absorption into kidney. This agent is expected antihypertensive and organ-protective effect.

- P2 study in essential hypertension in Japan was completed.
- P2 study in diabetes with albuminuria in Japan was completed.

Oncology

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Tivantinib	ARQ 197	Oral	Met inhibitor	Hepatocellular cancer	ArQule	TBD
<p><Summary> The molecular-targeted agent to inhibit HGF(hetatocyte growth factor) receptor, Met which has multiple roles in intracellular signal transductions such as cancer cell proliferation, angiogenesis, invasion, and apoptosis induction.</p> <p>• A P3 clinical study for HCC with MET high patients was started in Jan-2013.</p>						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Nimotuzumab	DE-766	Injection	Anti-EGFR antibody	Gastric cancer Esophageal cancer	InnoMab	TBD
<p><Summary> The humanized monoclonal antibody to target Epidermal Growth Factor Receptor(EGFR). This antibody is expected to be a best in class EGFR, safety against the skin toxicity and the effiacy comparable to the other antibodies.</p> <p>• P3 in Japan for NSCLC started in March 2013, that for Gastric cancer started in April 2013.</p>						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Patritumab	U3-1287	Injection	Anti-HER3 antibody	Non small cell lung cancer Breast cancer	Daiichi Sankyo (U3 Pharma)	TBD
<p><Summary> The fully human monoclonal antibody to target HER3, one of the Epidermal Growth Factor Receptor(EGFR) family of proteins. HER 3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are more potent to induce tumor cell proliferation than homodimers of HER2 or EGFR.</p>						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Vemurafenib	PLX4032	Oral	BRAF inhibitor	Colorectal cancer	Daiichi Sankyo (Plexxikon)	Zelboraf
<p><Summary> The molecular-targeted agent to inhibit BRAF V600E mutation. Launched since 2011 as personalized treatment for patients with unresectable or metastatic melanoma.</p>						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	PLX3397	Oral	Fms/Kit/Flt3-ITD inhibitor	Acute myeloid leukemia Glioblastoma Melanoma Pigmented villonodular synovitis	Daiichi Sankyo (Plexxikon)	TBD
<p><Summary> The molecular-targeted agent to inhibit Fms, Kit and Flt-ITD. This agent is expected to reduce tumor cell proliferation and expansion of metastases.</p>						

Others

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Denosumab	AMG 162	Injection	Anti-RANKL antibody	Breast cancer adjuvant Rheumatoid arthritis Giant cell tumor of bone	Amgen	SRE: Ranmark(JP) Osteoporosis: Pralia(JP)
<p><Summary></p> <p>The fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation. Launched in Japan in April 2012 as treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors, and in June 2013 as treatment for osteoporosis.</p> <ul style="list-style-type: none"> • July, 2007 In-licensed from Amgen. • P3 : Breast cancer adjuvant, Rheumatoid arthritis. • [JP] NDA approval: Skeletal Related Event(SRE) in Jan-2012, Osteoporosis in Mar-2013. • [JP] Filed for giant cell tumor of bone in Aug-2013. 						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Levofloxacin	DR-3355	Injection	New quinolone	Infection disease	Daiichi Sankyo	Cravit (JP) Levaquin (US) Tavanic (EU)
<p><Summary></p> <p>Levofloxacin injection formation, which was lauched in 2011for the treatment in respiratory tract infection. As LCM programme, the trials for urinary tract infection, surgical infection and gynecological infection are under-going.</p> <ul style="list-style-type: none"> • A P3 comparative study for urinary tract infection and 4 open studies are on-going. 						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Mirogabalin	DS-5565	Oral	$\alpha 2\delta$ ligand	Chronic pain	Daiichi Sankyo	TBD
<p><Summary></p> <p>The pain therapy agent to reduce the neurotransmitter release from nerve terminals. This agent is expected to show the good balanced efficacy and safety profile.</p> <ul style="list-style-type: none"> • Clinical studies are on-going for diabetic peripheral neuropathic pain 						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Hydromorphone	DS-7113	Oral/ Injection	opioid mu-receptor regulator	Cancer pain	-	TBD
<p><Summary></p> <p>The opiate, narcotic analgesic that has been available outside of Japan for over 80 years and recommended in WHO guideline as a standard analgesia for cancer pain. It is designated ed as unapproved drug by "Study Group on Unapproved and Off-label Drugs of High Medical Need".</p>						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	SUN13837	Injection	Modulator of bFGF signaling system	Spinal cord injury	Daiichi Sankyo (Asubio Pharma)	TBD
<p><Summary></p> <p>By accelerating self-regeneration capabilities (nerve cell protection, nerve axon elongation) with bFGF like cell differentiation actions, the perceptional and motor-functional dysfunctions caused by cord injuries are to be improved</p>						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Ioforninol	GE-145	Injection	X-ray contrast media	Angiography	GE Healthcare	TBD
<p><Summary></p> <p>Dimeric X-ray contrast medium, which is expected to reduce the sympton such as the feeling of warmth and pain.</p>						

MEMO

(This page is intentionally left blank)

1. Summary of Consolidated Income Statement (FY2012)

JPY Bn	Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	242.6	+4.7%	100%	241.6	+7.7%	100%	261.5	+8.8%	100%	252.2	+4.1%	100%	997.9	59.2	+6.3%
Cost of sales	27%	66.7	+11.2%	32%	77.2	+11.9%	33%	86.4	+20.6%	33%	83.4	+22.6%	31%	313.7	45.0	+16.8%
Gross Profit	73%	176.0	+2.5%	68%	164.4	+5.8%	67%	175.1	+3.8%	67%	168.8	-3.1%	69%	684.2	14.1	+2.1%
SG&A expenses	59%	143.4	+11.8%	58%	139.8	+2.3%	53%	138.6	-0.3%	64%	161.8	-3.6%	58%	583.7	11.8	+2.1%
R&D expenses	17%	42.0	+2.5%	19%	45.2	+5.1%	17%	44.6	-0.3%	20%	51.2	-8.9%	18%	183.0	-2.0	-1.1%
A&P expenses	9%	22.7	+9.6%	9%	21.6	-8.9%	10%	25.3	+2.0%	11%	27.2	+2.7%	10%	96.8	1.1	+1.1%
Personnel expenses	14%	34.7	-0.4%	14%	34.2	-4.1%	13%	34.1	+1.2%	16%	40.7	+17.0%	14%	143.7	4.7	+3.4%
Other SG&A expenses	18%	44.0	+39.0%	16%	38.9	+13.1%	13%	34.6	-3.2%	17%	42.7	-15.2%	16%	160.2	8.0	+5.3%
Operating Income	13%	32.5	-25.2%	10%	24.6	+31.2%	14%	36.5	+22.9%	3%	7.0	+10.2%	10%	100.5	2.3	+2.4%
Non-operating income / expenses		8.3			-15.5			9.4			-3.5			-1.4	20.6	
Non-operating income		10.3			-5.3			8.1			4.5			17.6	7.6	
Non-operating expenses		2.0			10.2			-1.2			8.0			19.0	-13.0	
Ordinary Income	17%	40.8	-9.0%	4%	9.0	-58.0%	18%	45.8	+128.3%	1%	3.5	-	10%	99.1	22.9	+30.1%
Extraordinary income / losses		0.6			-5.2			-5.7			3.3			-7.1	35.2	
Extraordinary income		2.0			0.5			0.7			8.9			12.1	-2.7	
Extraordinary losses		1.5			5.7			6.4			5.7			19.2	-37.9	
Income before income taxes and minority interests	17%	41.4	-5.5%	2%	3.8	-79.1%	15%	40.2	-	3%	6.7	-	9%	92.1	58.2	+171.5%
Income taxes / minority interests		21.0			-0.1			13.0			-8.4			25.5	1.9	
Income taxes		16.8			3.0			10.2			-6.0			23.9	-15.9	
Minority interests		4.2			-3.1			2.8			-2.4			1.6	17.8	
Net Income	8%	20.4	-19.4%	2%	4.0	-66.3%	10%	27.1	-	6%	15.1	-	7%	66.6	56.2	+541.6%
Effective tax rate		41%			78%			25%			-90%			26%		
Overseas sales ratio results		54%			48%			44%			49%			49%		

2. Currency Rate (FY2012)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2012
	Results	Results	Results	Results	Results
USD/JPY (average)	80.21	79.42	80.01	83.11	83.11
EUR/JPY (average)	102.91	100.64	102.18	107.15	107.15
INR/JPY (average)	1.59	1.54	1.50	1.50	1.50
					YoY
					+4.04
					-1.81
					-0.23

3. Segment Information (FY2012)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		183.5	-4.4%		193.9	+4.3%		223.1	+9.0%		211.9	+17.3%		812.4	49.2	+6.5%
Inter-segment sales		0.3			0.3			0.7			0.5			1.8	1.3	
Net sales	100%	183.8	-4.2%	100%	194.2	+4.4%	100%	223.8	+9.2%	100%	212.4	+17.6%	100%	814.2	50.6	+6.6%
Cost of sales	26%	47.9	+16.4%	29%	56.1	+16.2%	30%	67.3	+28.1%	29%	61.2	+35.5%	29%	232.5	45.3	+24.2%
Gross Profit	74%	135.9	-9.9%	71%	138.1	+0.3%	70%	156.5	+2.6%	71%	151.1	+11.6%	71%	581.7	5.2	+0.9%
SG&A expenses	63%	115.9	+4.2%	61%	117.8	-1.1%	54%	121.8	-0.4%	67%	142.3	+1.5%	61%	497.8	4.9	+1.0%
R&D expenses	22%	40.3	+3.1%	22%	43.2	+5.4%	19%	42.8	+0.2%	23%	49.3	-9.2%	22%	175.5	-1.4	-0.8%
Other expenses	41%	75.6	+4.8%	38%	74.6	-4.5%	35%	79.0	-0.8%	44%	93.0	+8.2%	40%	322.2	6.3	+2.0%
Operating Income	11%	20.1	-49.3%	10%	20.3	+8.9%	16%	34.7	+15.1%	4%	8.9	-	10%	84.0	0.3	+0.4%
Non-operating income		2.1			1.0			2.5			1.7			7.3	-0.8	
Non-operating expenses		1.0			1.6			1.2			1.8			5.6	0.8	
Ordinary Income	11%	21.1	-49.2%	10%	19.8	+4.2%	16%	36.1	+16.1%	4%	8.8	-	11%	85.7	-1.3	-1.4%
Extraordinary income		2.0			0.4			0.6			8.9			11.9	-2.4	
Extraordinary losses		1.3			5.7			6.3			2.5			15.8	0.1	
Income before income taxes and minority interests	12%	21.8	-46.2%	7%	14.5	-8.3%	14%	30.4	+2.8%	7%	15.2	-	10%	81.8	-3.8	-4.4%
Income taxes		8.1			4.4			6.9			-4.7			14.7	-36.6	
Minority interests		-0.1			-0.0			0.2			-0.0					
Net Income	7%	13.7	-40.1%	5%	10.2	-4.6%	10%	23.2	+110.3%	9%	19.9	-	8%	67.0	29.7	+79.4%

Ranbaxy Group																
Sales to outside customers		59.1	+48.7%		47.6	+24.0%		38.3	+7.5%		40.3	-34.6%		185.4	9.9	+5.7%
Inter-segment sales		0.7			0.3			0.3			0.4			1.7	0.6	
Net sales	100%	59.8	+49.5%	100%	47.9	+24.1%	100%	38.6	+7.5%	100%	40.8	-34.3%	100%	187.1	10.5	+6.0%
Cost of sales	33%	19.5	+3.7%	45%	21.5	+3.7%	52%	20.1	+3.0%	56%	22.9	+0.6%	45%	83.9	2.2	+2.7%
Gross Profit	67%	40.3	+90.0%	55%	26.5	+47.7%	48%	18.5	+12.9%	44%	17.9	-54.5%	55%	103.2	8.4	+8.8%
SG&A expenses	44%	26.5	+66.2%	44%	20.9	+28.3%	41%	15.7	+0.5%	45%	18.4	-31.2%	44%	81.4	6.9	+9.3%
R&D expenses	3%	2.0	-12.3%	4%	2.1	-10.7%	5%	1.9	-17.0%	5%	2.1	-11.6%	4%	8.1	-1.2	-12.9%
Other expenses	41%	24.5	+79.4%	39%	18.7	+35.1%	36%	13.8	+3.6%	40%	16.3	-33.0%	39%	73.3	8.1	+12.5%
Operating Income	23%	13.8	+161.9%	12%	5.6	+238.2%	7%	2.9	+238.4%	-1%	-0.5	-103.9%	12%	21.8	1.4	+7.0%
Non-operating income		8.3			-6.2			5.7			2.8			10.4	7.3	
Non-operating expenses		0.8			8.6			-2.5			6.2			13.2	-13.9	
Ordinary Income	36%	21.2	+269.3%	-19%	-9.2	-317.5%	29%	11.0	-	-10%	-3.9	-	10%	19.1	22.6	-
Extraordinary income		0.0			0.0			0.0			0.0			0.1	-0.9	
Extraordinary losses		0.1			-0.0			0.0			3.2			3.4	-38.0	
Income before income taxes and minority interests	35%	21.1	+267.8%	-19%	-9.2	-321.2%	29%	11.0	-	-17%	-7.1	-	9%	15.9	59.6	-
Income taxes		6.1			-2.3			3.6			-1.1			6.3	16.5	
Minority interests		0.0			0.0			0.1			0.1			0.2	0.0	
Net Income	25%	15.0	+118.9%	-14%	-6.9	-297.1%	19%	7.4	-	-15%	-6.1	-	5%	9.4	43.1	-

Inter-segment Transactions																
Net sales		-1.0			-0.6			-1.0			-0.9			-3.5		
Cost of sales		-0.7			-0.4			-0.9			-0.7			-2.7		
Gross Profit		-0.3			-0.2			-0.0			-0.2			-0.7		
SG&A expenses		1.1			1.2			1.1			1.2			4.6		
R&D expenses		-0.3			-0.1			-0.1			-0.1			-0.6		
Other expenses		1.4			1.3			1.3			1.3			5.2		
Operating Income		-1.4			-1.4			-1.1			-1.4			-5.3		
Non-operating income		-0.0			-0.1			-0.1			0.0			-0.2		
Non-operating expenses		0.1			0.0			0.0			0.0			0.2		
Ordinary Income		-1.5			-1.5			-1.2			-1.4			-5.7		
Extraordinary income		-			0.0			0.0			0.1			0.1		
Extraordinary losses		0.0			-0.0			0.0			0.0			0.0		
Income before income taxes and minority interests		-1.5			-1.5			-1.2			-1.4			-5.6		
Income taxes		2.6			0.9			-0.3			-0.3			3.0		
Minority interests		4.2			-3.1			2.6			-2.4			1.3		
Net Income		-8.3			0.7			-3.5			1.3			-9.8		

4. Sales by Business Units (FY2012)

	FY2012 Plan	Q1			Q2			Q3			Q4			FY2012		
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn																
Consolidated Net Sales	990.0	242.6	+4.7%	25%	241.6	+7.7%	24%	261.5	+8.8%	26%	252.2	+4.1%	26%	997.9	+6.3%	101%
Japan Company (domestic sales)	440.0	98.2	-2.2%	22%	106.9	+6.3%	24%	124.7	+9.5%	28%	112.7	+18.8%	26%	442.5	+8.0%	101%
Olmetec	76.0	18.2	-10.8%	24%	19.3	-5.5%	25%	20.9	-7.6%	28%	19.9	+14.3%	26%	78.3	-3.2%	103%
Rezaltas	16.0	4.0	+38.6%	25%	4.1	+30.6%	26%	4.6	+16.9%	28%	4.3	+20.5%	27%	16.9	+25.7%	106%
Calblock	10.0	2.7	-14.0%	27%	2.8	-12.9%	28%	2.8	-13.8%	28%	2.6	-5.5%	26%	10.9	-11.8%	109%
Loxonin	60.0	14.1	-2.0%	24%	15.6	-0.4%	26%	16.2	-6.1%	27%	13.7	+0.0%	23%	59.6	-2.3%	99%
Cravit	35.0	8.1	-4.2%	23%	8.4	+0.0%	24%	10.6	-2.0%	30%	8.8	+1.6%	25%	35.9	-1.2%	103%
Nexium	22.0	1.7	-	8%	2.7	+7.1%	13%	8.3	+1254.8%	38%	8.9	+1113.9%	40%	21.6	+452.0%	98%
Memary	26.0	5.1	+128.7%	20%	5.6	+247.5%	22%	6.6	+135.7%	25%	6.4	+103.0%	25%	23.8	+142.0%	92%
Mevalotin	26.0	6.5	-25.7%	25%	6.8	-21.8%	26%	6.6	-25.6%	25%	6.0	-12.4%	23%	25.8	-21.9%	99%
Artist	22.0	5.6	-8.9%	25%	5.6	-9.3%	26%	5.8	-10.9%	27%	5.3	-5.6%	24%	22.4	-8.8%	102%
Omnipaque	20.0	4.9	-13.2%	25%	5.3	-15.9%	26%	5.4	-16.3%	27%	4.6	-11.1%	23%	20.2	-14.3%	101%
Urief	11.0	2.7	+0.5%	24%	2.8	+0.1%	25%	3.0	-1.8%	27%	2.7	+5.7%	25%	11.1	+1.0%	101%
Inavir	11.0	0.4	+10.3%	4%	0.1	-164.9%	1%	2.1	+22.9%	19%	8.6	-2.0%	78%	11.1	+3.8%	101%
Ranmark	5.0	0.6	-	12%	1.1	-	22%	1.3	-	27%	1.4	-	27%	4.4	-	88%
Vaccines	not disclosed	5.2	+13.9%	-	8.1	+52.5%	-	11.8	+72.2%	-	4.7	+3.5%	-	29.8	+40.2%	-
Daiichi Sankyo Espha products	not disclosed	2.8	+16.2%	-	2.7	+12.7%	-	3.0	+2.4%	-	2.6	+20.7%	-	11.1	+12.2%	-
Daiichi Sankyo Healthcare (OTC)	48.0	10.2	+5.0%	21%	12.8	+1.1%	27%	14.5	+6.1%	30%	9.5	-2.4%	20%	47.1	+2.7%	98%
Daiichi Sankyo, Inc. (US)	139.0	35.9	+3.7%	26%	32.6	+10.0%	24%	37.4	+23.9%	27%	36.4	+11.6%	26%	142.3	+12.0%	102%
Olmesartan	93.0	23.9	-3.8%	26%	21.7	+6.3%	23%	25.7	+24.9%	28%	23.6	+7.0%	25%	94.9	+7.9%	102%
Benicar/Benicar HCT	73.0	18.9	-6.3%	26%	16.7	-0.6%	23%	20.2	+24.7%	28%	17.4	-3.8%	24%	73.2	+2.8%	100%
Azor	14.0	3.5	-1.7%	25%	3.5	+40.0%	25%	3.8	+20.9%	27%	4.1	+42.7%	29%	14.8	+23.3%	106%
Tribenzor	6.0	1.6	+30.8%	26%	1.5	+34.3%	25%	1.6	+37.1%	27%	2.1	+90.9%	35%	6.8	+47.8%	114%
Welchol	31.0	8.3	+17.5%	27%	7.2	+10.5%	23%	8.3	+26.1%	27%	9.3	+39.4%	30%	33.1	+23.4%	107%
Effient (alliance revenue)	not disclosed	2.4	+51.8%	-	2.3	+36.4%	-	2.7	+47.5%	-	3.0	+9.5%	-	10.5	+32.7%	-
Luitpold Pharmaceuticals, Inc. (US)	38.0	11.3	-10.9%	30%	7.7	-17.4%	20%	11.3	-24.7%	30%	8.2	+7.7%	22%	38.6	-13.7%	102%
Venofer	23.0	6.8	-7.4%	30%	3.8	-30.4%	17%	8.3	-8.5%	36%	4.7	+60.9%	20%	23.6	-4.9%	103%
Daiichi Sankyo Europe GmbH	65.0	13.9	-17.6%	21%	15.1	-10.8%	23%	16.9	-2.6%	26%	18.5	-3.0%	29%	64.4	-8.3%	99%
Olmesartan	48.0	9.9	-16.6%	21%	11.3	-6.6%	24%	12.9	+1.8%	27%	13.9	-3.1%	29%	48.0	-5.9%	100%
Olmetec/Olmetec Plus	34.0	6.4	-26.5%	19%	8.1	-7.6%	24%	8.6	-6.9%	25%	9.4	-4.5%	28%	32.6	-11.1%	96%
Sevikar	10.0	2.5	+4.5%	25%	2.3	-12.2%	23%	3.1	+17.4%	31%	2.9	-13.7%	29%	10.8	-2.0%	108%
Sevikar HCT	4.0	1.0	+31.6%	24%	0.9	+25.7%	23%	1.3	+47.9%	32%	1.5	+43.3%	38%	4.7	+38.2%	117%
Efient (alliance revenue)	not disclosed	0.9	+54.7%	-	0.9	+40.5%	-	0.9	+33.0%	-	1.2	+13.0%	-	3.9	+31.9%	-
Asia, South and Central America (ASCA)^{*1}	38.0	7.1	+9.8%	19%	8.1	+10.1%	21%	8.2	+18.4%	22%	17.1	+117.8%	45%	40.5	+41.6%	107%
Daiichi Sankyo China ^{*2}	not disclosed	2.7	+0.9%	-	3.0	+16.0%	-	3.1	+50.9%	-	7.6	+214.7%	-	16.4	+68.8%	-
Daiichi Sankyo Taiwan	not disclosed	0.8	-5.9%	-	0.8	-1.3%	-	0.8	+7.8%	-	0.9	+19.5%	-	3.3	+4.7%	-
Daiichi Sankyo Korea	not disclosed	1.2	+2.1%	-	1.2	+5.5%	-	1.3	+16.8%	-	1.6	+40.0%	-	5.3	+15.8%	-
Daiichi Sankyo (Thailand)	not disclosed	0.3	+3.7%	-	0.3	+2.7%	-	0.4	+14.5%	-	0.4	+38.7%	-	1.4	+15.6%	-
Daiichi Sankyo Brasil Farmacêutica	not disclosed	1.2	+14.2%	-	1.2	-22.5%	-	1.0	-34.4%	-	3.2	+118.5%	-	6.6	+18.6%	-
Daiichi Sankyo Venezuela	not disclosed	0.8	+87.0%	-	1.4	+49.5%	-	1.5	+37.1%	-	2.9	+75.9%	-	6.7	+60.7%	-
Daiichi Sankyo Mexico S.A. de C.V	not disclosed	0.1	-	-	0.1	-	-	0.1	-	-	0.4	-	-	0.7	-	-
Ranbaxy Laboratories Limited	179.0	59.1	+48.7%	33%	47.6	+24.0%	27%	38.3	+7.5%	21%	40.3	-34.6%	23%	185.4	+5.7%	104%
Others	43.0	6.8	-38.0%	16%	10.7	+13.1%	25%	10.0	+32.8%	23%	9.5	+7.5%	22%	37.1	+0.5%	86%
Levofloxacin export, royalty, etc	3.0	1.2	-60.1%	41%	1.0	-56.6%	34%	1.4	+19.3%	46%	0.6	-59.6%	21%	4.3	-47.8%	142%
Plexxikon	not disclosed	0.1	-96.1%	-	1.4	-24.6%	-	1.0	+313.4%	-	0.5	-35.9%	-	3.1	-47.7%	-

[Reference] Sales in Local Currency

		FY2012	Q1			Q2			Q3			Q4			FY2012		
		Plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
USD Mn																	
Daiichi Sankyo, Inc. (US)		1,711	448	+5.7%	26%	415	+8.7%	24%	461.0	+18.2%	27%	389.0	-5.6%	23%	1,713	+6.5%	100%
Olmesartan		1,144	298	-2.0%	26%	276	+4.9%	24%	317	+19.0%	28%	251	-9.9%	22%	1,142	+2.7%	100%
Benicar/Benicar HCT		898	235	-4.5%	26%	213	-1.8%	24%	249	+18.8%	28%	184	-19.6%	20%	881	-2.2%	98%
Azor		172	44	+0.2%	25%	44	+37.4%	26%	47	+15.5%	27%	44	+22.2%	25%	179	+17.3%	104%
Tribenzor		75	19	+33.3%	26%	19	+33.0%	26%	20	+30.9%	27%	23	+66.5%	31%	82	+40.6%	109%
Welchol		388	103	+19.7%	27%	92	+9.5%	24%	103	+20.3%	27%	101	+19.8%	26%	399	+17.4%	103%
Effient (alliance revenue)		not disclosed	30	+54.7%	-	30	+35.4%	-	34	+41.2%	-	33	-5.7%	-	127	+26.2%	-
USD Mn																	
Luitpold Pharmaceuticals, Inc. (US)		468	141	-9.2%	30%	98	-18.5%	21%	140.0	-27.6%	30%	85.0	-11.8%	18%	465	-17.9%	99%
Venofer		288	85	-5.6%	30%	49	-31.0%	17%	103	-11.8%	36%	47	+29.8%	16%	284	-9.6%	99%
EUR Mn																	
Daiichi Sankyo Europe GmbH		650	135	-6.0%	21%	153	-0.2%	24%	161.0	-2.6%	25%	152.0	-16.6%	23%	601	-6.7%	93%
Olmesartan		480	96	-4.8%	20%	115	+4.4%	24%	123	+2.0%	26%	114	-16.5%	24%	448	-4.3%	93%
Olmetec/Olmetec Plus		340	62	-16.2%	18%	82	+3.1%	24%	82	-6.8%	24%	78	-17.8%	23%	304	-9.6%	89%
Sevikar		100	24	+19.3%	25%	23	-1.1%	24%	29	+17.7%	29%	23	-26.4%	23%	100	-0.3%	100%
Sevikar HCT		40	9	+50.1%	24%	9	+41.0%	23%	12	+49.4%	30%	13	+27.1%	32%	44	+40.5%	109%
Efient (alliance revenue)		not disclosed	9	+76.5%	-	9	+57.9%	-	9	+33.5%	-	10	-1.0%	-	36	+34.1%	-
INR Bn																	
Ranbaxy Laboratories Limited		105	37	+71.1%	35%	32	+53.1%	31%	27.0	+31.2%	26%	27.0	-28.9%	26%	124	+21.9%	117%

5. Sales of Global Products (FY2012)

		FY2012	Q1			Q2			Q3			Q4			FY2012		
		Plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn																	
Olmesartan		251.0	60.0	-5.3%	24%	60.8	+0.6%	24%	68.3	+6.4%	27%	69.7	+13.0%	28%	258.9	+3.7%	103%
Olmetec (JPN)		76.0	18.2	-10.8%	24%	19.3	-5.5%	25%	20.9	-7.6%	28%	19.9	+14.3%	26%	78.3	-3.2%	103%
Rezaltas (JPN)		16.0	4.0	+38.6%	25%	4.1	+30.6%	26%	4.6	+16.9%	28%	4.3	+20.5%	27%	16.9	+25.7%	106%
Benicar/Benicar HCT (US)		73.0	18.9	-6.3%	26%	16.7	-0.6%	23%	20.2	+24.7%	28%	17.4	-3.8%	24%	73.2	+2.8%	100%
Azor (US)		14.0	3.5	-1.7%	25%	3.5	+40.0%	25%	3.8	+20.9%	27%	4.1	+42.7%	29%	14.8	+23.3%	106%
Tribenzor (US)		6.0	1.6	+30.8%	26%	1.5	+34.3%	25%	1.6	+37.1%	27%	2.1	+90.9%	35%	6.8	+47.8%	114%
Olmetec/Olmetec Plus (EU)		34.0	6.4	-26.5%	19%	8.1	-7.6%	24%	8.6	-6.9%	25%	9.4	-4.5%	28%	32.6	-11.1%	96%
Sevikar (EU)		10.0	2.5	+4.5%	25%	2.3	-12.2%	23%	3.1	+17.4%	31%	2.9	-13.7%	29%	10.8	-2.0%	108%
Sevikar HCT (EU)		4.0	1.0	+31.6%	24%	0.9	+25.7%	23%	1.3	+47.9%	32%	1.5	+43.3%	38%	4.7	+38.2%	117%
Other subsidiaries, export, etc		18.0	4.0	+20.6%	22%	4.3	+0.1%	24%	4.3	-3.1%	24%	8.1	+82.8%	45%	20.7	+25.7%	115%
Prasugrel		not disclosed	3.3	+52.6%	-	3.2	+37.5%	-	3.7	+43.5%	-	4.2	+10.4%	-	14.4	+32.5%	-
Effient alliance revenue (US)		not disclosed	2.4	+51.8%	-	2.3	+36.4%	-	2.7	+47.5%	-	3.0	+9.5%	-	10.5	+32.7%	-
Efient alliance revenue (EU)		not disclosed	0.9	+54.7%	-	0.9	+40.5%	-	0.9	+33.0%	-	1.2	+13.0%	-	3.9	+31.9%	-

1. Summary of Consolidated Income Statement (FY2011)

JPY Bn	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	231.7	-9.7%	100%	224.4	-7.5%	100%	240.4	-3.5%	100%	242.3	+10.5%	100%	938.7	-28.7	-3.0%
Cost of sales	26%	59.9	-6.5%	31%	69.0	-7.4%	30%	71.7	-3.9%	28%	68.1	-0.8%	29%	268.6	-13.1	-4.6%
Gross Profit	74%	171.8	-10.7%	69%	155.4	-7.5%	70%	168.7	-3.4%	72%	174.2	+15.6%	71%	670.1	-15.6	-2.3%
SG&A expenses	55%	128.3	-2.3%	61%	136.7	-1.6%	58%	139.0	-3.5%	69%	167.9	+12.5%	61%	571.9	8.3	+1.5%
R&D expenses	18%	41.0	-5.9%	19%	43.0	-5.8%	19%	44.7	-15.6%	23%	56.3	+8.2%	20%	185.1	-9.3	-4.8%
A&P expenses	9%	20.7	-9.4%	11%	23.7	-4.6%	10%	24.8	-4.1%	11%	26.5	+1.4%	10%	95.7	-4.0	-4.0%
Personnel expenses	15%	34.9	+0.8%	16%	35.6	+0.5%	14%	33.7	+1.9%	14%	34.8	+0.0%	15%	139.0	1.1	+0.8%
Other SG&A expenses	14%	31.6	+4.6%	15%	34.4	+4.1%	15%	35.7	+11.3%	21%	50.4	+38.7%	16%	152.1	20.4	+15.5%
Operating Income	19%	43.5	-28.8%	8%	18.7	-35.6%	12%	29.7	-2.8%	3%	6.3	+318.5%	10%	98.2	-23.9	-19.6%
Non-operating income / expenses		1.4			2.8			-9.6			-16.5			-22.0	-31.6	
Non-operating income		4.5			4.8			-1.0			1.7			10.0	-13.2	
Non-operating expenses		3.1			2.0			8.6			18.3			32.0	18.4	
Ordinary Income	19%	44.8	-36.0%	10%	21.5	-4.6%	8%	20.1	-47.1%	-4%	-10.2	-	8%	76.2	-55.5	-42.2%
Extraordinary income / losses		-1.1			-3.2			-41.7			3.7			-42.3	-31.0	
Extraordinary income		1.2			0.7			0.2			12.7			14.8	2.0	
Extraordinary losses		2.3			4.0			41.9			9.0			57.1	32.9	
Income before income taxes and minority interests	19%	43.8	-33.8%	8%	18.3	-34.8%	-9%	-21.6	-	-3%	-6.5	-	4%	33.9	-86.5	-71.8%
Income taxes / minority interests		18.5			6.5			-2.1			0.7			23.5	-26.8	
Income taxes		16.4			6.3			15.2			1.8			39.8	-2.0	
Minority interests		2.1			0.2			-17.4			-1.2			-16.2	-24.7	
Net Income	11%	25.3	-23.5%	5%	11.7	-38.5%	-8%	-19.5	-	-3%	-7.2	-	1%	10.4	-59.7	-85.2%
Effective tax rate		37%			34%			-			-			117%		
Overseas sales ratio results		51%			48%			45%			56%			50%		

2. Currency Rate (FY2011)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2011	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	81.75	79.81	79.00	79.07	79.07	-6.65
EUR/JPY (average)	117.40	113.78	110.62	108.96	108.96	-4.17
INR/JPY (average)	1.83	1.83	1.79	1.73	1.73	-0.20

3. Segment Information (FY2011)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		191.9	-4.8%		185.9	-6.5%		204.7	-4.2%		180.6	-0.4%		763.2	-32.2	-4.2%
Inter-segment sales		0.1			0.1			0.3			-0.0			0.5	0.4	
Net sales	100%	192.0	-4.8%	100%	186.0	-6.4%	100%	205.0	-4.1%	100%	180.6	-0.4%	100%	763.6	-31.8	-4.0%
Cost of sales	21%	41.1	-8.4%	26%	48.3	-11.2%	26%	52.5	-4.4%	25%	45.2	-5.0%	25%	187.1	-14.7	-7.3%
Gross Profit	79%	150.8	-3.8%	74%	137.7	-4.6%	74%	152.5	-3.9%	75%	135.4	+1.2%	76%	576.5	-17.2	-2.9%
SG&A expenses	58%	111.2	-2.0%	64%	119.1	-1.8%	60%	122.3	-4.2%	78%	140.2	+6.6%	65%	492.8	-1.0	-0.2%
R&D expenses	20%	39.1	-3.1%	22%	40.9	-5.9%	21%	42.7	-15.6%	30%	54.2	+9.4%	23%	177.0	-7.0	-3.8%
Other expenses	38%	72.1	-1.4%	42%	78.1	+0.5%	39%	79.6	+3.3%	48%	86.0	+5.0%	41%	315.9	6.0	+1.9%
Operating Income	21%	39.6	-8.5%	10%	18.7	-19.4%	15%	30.2	-2.9%	-3%	-4.8	-	11%	83.7	-16.1	-16.2%
Non-operating income		3.8			1.7			1.6			1.0			8.1	0.9	
Non-operating expenses		1.8			1.4			0.7			0.9			4.8	-2.3	
Ordinary Income	22%	41.6	-4.2%	10%	19.0	-17.8%	15%	31.1	-7.9%	-3%	-4.6	-	11%	87.0	-13.0	-13.0%
Extraordinary income		1.2			0.7			-0.0			12.5			14.3	4.1	
Extraordinary losses		2.3			3.8			1.5			8.1			15.7	-5.2	
Income before income taxes and minority interests	21%	40.4	+1.2%	9%	15.8	-38.9%	14%	29.5	-14.2%	0%	-0.2	-	11%	85.6	-3.7	-4.2%
Income taxes		17.8			5.9			18.9			8.6			51.2	20.7	
Minority interests		-0.2			-0.8			-0.4			-1.6					
Net Income	12%	22.9	+2.5%	6%	10.7	-41.9%	5%	11.0	-57.5%	-4%	-7.2	-	5%	37.4	-21.4	-36.4%
Ranbaxy Group																
Sales to outside customers		39.8	-27.5%		38.4	-12.0%		35.7	+0.6%		61.6	+62.3%		175.5	3.6	+2.0%
Inter-segment sales		0.2			0.2			0.2			0.4			1.1	-0.0	
Net sales	100%	40.0	-27.1%	100%	38.6	-11.7%	100%	35.9	+1.1%	100%	62.0	+59.5%	100%	176.6	3.5	+2.0%
Cost of sales	47%	18.8	-2.2%	54%	20.7	+3.3%	54%	19.5	-0.1%	37%	22.8	+8.2%	46%	81.7	2.0	+2.5%
Gross Profit	53%	21.2	-40.6%	46%	17.9	-24.5%	46%	16.4	+2.5%	63%	39.3	+120.0%	54%	94.8	1.5	+1.7%
SG&A expenses	40%	15.9	-2.6%	42%	16.3	-5.0%	43%	15.6	+1.2%	43%	26.7	+59.6%	42%	74.4	8.9	+13.5%
R&D expenses	6%	2.3	-30.8%	6%	2.4	-21.3%	6%	2.3	-19.1%	4%	2.3	-17.9%	5%	9.3	-2.7	-22.6%
Other expenses	34%	13.7	+4.5%	36%	13.9	-1.4%	37%	13.3	+5.8%	39%	24.3	+75.4%	37%	65.1	11.6	+21.6%
Operating Income	13%	5.3	-72.7%	4%	1.7	-74.9%	2%	0.9	+34.5%	20%	12.6	+998.6%	12%	20.4	-7.3	-26.4%
Non-operating income		1.7			3.1			-2.5			0.8			3.2	-13.0	
Non-operating expenses		1.3			0.5			7.9			17.4			27.0	23.1	
Ordinary Income	14%	5.8	-79.6%	11%	4.2	+353.5%	-26%	-9.5	-	-6%	-3.9	-	-2%	-3.4	-43.4	-
Extraordinary income		0.0			0.0			0.8			0.2			1.1	-4.1	
Extraordinary losses		0.0			0.1			0.0			41.2			41.4	33.1	
Income before income taxes and minority interests	14%	5.7	-79.2%	11%	4.2	-31.2%	-24%	-8.7	-	-72%	-45.0	-	-25%	-43.8	-80.6	-
Income taxes		-1.1			0.6			-3.2			-6.5			-10.2	-23.4	
Minority interests		0.0			0.0			0.0			0.0			0.2	-0.1	
Net Income	17%	6.9	-62.7%	9%	3.5	-22.7%	-16%	-5.6	-	-62%	-38.5	-	-19%	-33.7	-57.1	-
Inter-segment Transactions																
Net sales		-0.3			-0.3			-0.6			-0.4			-1.5		
Cost of sales		0.0			-0.1			-0.3			0.1			-0.3		
Gross Profit		-0.3			-0.2			-0.2			-0.5			-1.3		
SG&A expenses		1.1			1.4			1.1			1.0			4.6		
R&D expenses		-0.4			-0.3			-0.3			-0.3			-1.2		
Other expenses		1.4			1.7			1.4			1.3			5.8		
Operating Income		-1.4			-1.6			-1.3			-1.5			-5.9		
Non-operating income		-1.1			-0.1			-0.1			-0.1			-1.3		
Non-operating expenses		0.0			0.0			0.1			0.0			0.1		
Ordinary Income		-2.5			-1.7			-1.5			-1.7			-7.3		
Extraordinary income		0.1			0.0			-0.7			0.0			-0.6		
Extraordinary losses								40.3			-40.3			0.0		
Income before income taxes and minority interests		-2.4			-1.7			-42.5			38.7			-7.9		
Income taxes		-0.3			-0.2			-0.5			-0.2			-1.3		
Minority interests		2.3			1.0			-17.0			0.4			-13.4		
Net Income		-4.4			-2.4			-24.9			38.5			6.7		

4. Sales by Business Units (FY2011)

JPY Bn	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
Consolidated Net Sales	231.7	-9.7%	24%	224.4	-7.5%	23%	240.4	-3.5%	25%	242.3	+10.5%	25%	938.7	-3.0%	97%
Japan Company (domestic sales)	100.4	-4.6%	23%	100.5	-2.4%	23%	113.9	-2.4%	26%	94.9	+4.3%	22%	409.8	-1.5%	94%
Olmetec	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Calblock	3.2	-13.4%	21%	3.2	-9.4%	21%	3.3	-13.8%	22%	2.7	-7.5%	18%	12.4	-11.3%	83%
Loxonin	14.4	+10.7%	25%	15.7	+13.3%	27%	17.2	+17.6%	30%	13.7	+8.3%	24%	61.0	+12.7%	105%
Cravit	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Nexium	-	-	-	2.6	-	-	0.6	-	-	0.7	-	-	3.9	-	-
Memary	2.2	-	-	1.6	-	-	2.8	-	-	3.2	-	-	9.8	-	-
Mevalotin	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Artist	6.1	+0.0%	27%	6.2	+6.8%	27%	6.5	+3.6%	29%	5.6	+3.7%	25%	24.5	+3.5%	107%
Omnipaque	5.7	-11.6%	25%	6.3	-5.1%	27%	6.4	-2.0%	28%	5.2	-4.5%	23%	23.5	-5.8%	102%
Urief	2.6	+6.8%	24%	2.8	+13.6%	25%	3.0	+7.6%	27%	2.6	+9.2%	23%	11.0	+9.3%	100%
Inavir	0.4	-	4%	-0.1	-	-	1.7	-38.5%	19%	8.7	+125.1%	97%	10.7	+61.7%	119%
Vaccines	4.6	+166.4%	-	5.3	+14.8%	-	6.9	-19.7%	-	4.5	+56.5%	-	21.2	+19.6%	-
Daiichi Sankyo Espha products	2.4	-	-	2.4	-	-	2.9	-	-	2.1	-	-	9.9	-	-
Daiichi Sankyo Healthcare (OTC)	9.7	+4.9%	20%	12.7	+8.2%	26%	13.7	+4.1%	28%	9.7	-8.5%	20%	45.9	+2.3%	94%
Daiichi Sankyo, Inc. (US)	34.6	+3.2%	27%	29.7	-12.4%	23%	30.1	-13.0%	23%	32.6	+15.0%	25%	127.1	-2.6%	98%
Olmesartan	24.9	-1.5%	28%	20.4	-17.4%	23%	20.6	-16.3%	23%	22.1	+10.7%	25%	87.9	-6.9%	100%
Benicar/Benicar HCT	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Welchol	7.0	+0.5%	22%	6.5	-11.5%	20%	6.6	-16.0%	21%	6.7	+6.7%	21%	26.9	-5.8%	84%
Effient (alliance revenue)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Luitpold Pharmaceuticals, Inc. (US)	12.7	-13.6%	26%	9.3	-31.7%	19%	15.0	+31.0%	31%	7.6	-45.6%	16%	44.7	-17.0%	91%
Venofer	7.4	-12.5%	30%	5.5	-28.5%	22%	9.1	+55.6%	36%	2.9	-66.8%	12%	24.8	-19.0%	99%
Daiichi Sankyo Europe GmbH	16.9	+14.0%	22%	16.9	+2.0%	22%	17.4	-4.3%	23%	19.1	+13.0%	25%	70.2	+5.7%	91%
Olmesartan	11.9	+23.5%	22%	12.2	+4.2%	22%	12.7	-5.4%	23%	14.3	+24.4%	26%	51.0	+10.5%	93%
Olmetec/Olmetec Plus	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Efient (alliance revenue)	0.6	-	-	0.6	-	-	0.7	-	-	1.0	-	-	2.9	-	-
Asia, South and Central America (ASCA)	6.5	+8.7%	22%	7.3	+3.8%	24%	6.9	+2.0%	23%	7.8	+2.8%	26%	28.6	+4.1%	95%
Daiichi Sankyo Pharmaceutical (Beijing)	0.9	-19.9%	-	0.9	-15.0%	-	0.8	-28.4%	-	0.8	-11.1%	-	3.4	-18.9%	-
Daiichi Sankyo Pharmaceutical (Shanghai)	1.7	+21.9%	-	1.7	-3.8%	-	1.3	-18.7%	-	1.6	-11.3%	-	6.3	-3.9%	-
Daiichi Sankyo Taiwan	0.8	+4.6%	-	0.8	-2.8%	-	0.8	-2.7%	-	0.8	-21.0%	-	3.1	-6.3%	-
Daiichi Sankyo Korea	1.2	+23.0%	-	1.1	+27.0%	-	1.1	+14.6%	-	1.1	-0.7%	-	4.6	+15.2%	-
Daiichi Sankyo (Thailand)	0.3	+10.1%	-	0.3	+2.3%	-	0.3	-1.6%	-	0.3	-7.5%	-	1.2	-0.1%	-
Daiichi Sankyo Brasil Farmacêutica	1.1	+2.6%	-	1.5	+4.4%	-	1.5	+6.7%	-	1.5	+13.1%	-	5.5	+6.9%	-
Daiichi Sankyo Venezuela	0.5	+22.5%	-	1.0	+33.2%	-	1.1	+74.6%	-	1.6	+43.6%	-	4.2	+45.1%	-
Daiichi Sankyo Mexico S.A. de C.V	-	-	-	-	-	-	0.1	-	-	0.1	-	-	0.2	-	-
Ranbaxy Laboratories Limited	39.8	-27.5%	25%	38.4	-12.0%	24%	35.7	+0.6%	22%	61.6	+62.3%	38%	175.5	+2.1%	108%
Others	11.1	-38.7%	29%	9.5	-25.9%	25%	7.5	-40.5%	20%	8.8	-31.2%	23%	36.9	-34.5%	97%
Levofloxacin export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Plexxikon	3.0	-	-	1.9	-	-	0.3	-	-	0.8	-	-	5.9	-	-

[Reference] Sales in Local Currency

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
USD Mn															
Daiichi Sankyo, Inc. (US)	424	+16.1%	27%	382	-2.9%	24%	390	-7.5%	25%	412.0	+20.3%	26%	1,608	+5.6%	103%
Olmesartan	304	+10.9%	29%	263	-8.4%	25%	266	-11.2%	25%	278	+15.7%	26%	1,112	+0.9%	105%
Benicar/Benicar HCT	246	+5.7%	31%	217	-10.0%	27%	210	-16.5%	26%	228	+11.5%	28%	901	-3.1%	112%
Azor	43	+4.7%	27%	32	-18.4%	20%	41	-3.5%	25%	36	+11.9%	22%	152	-1.9%	94%
Tribenzor	14	-	16%	14	+96.0%	16%	15	+158.0%	17%	14	+287.9%	16%	58	+244.1%	65%
Welchol	86	+13.2%	22%	84	-1.9%	22%	85	-10.5%	22%	84	+11.6%	22%	340	+2.1%	88%
Effient (alliance revenue)	20	+401.5%	-	22	+151.6%	-	24	+90.2%	-	35	+134.1%	-	100	+150.1%	-
USD Mn															
Luitpold Pharmaceuticals, Inc. (US)	156	-2.8%	26%	121	-24.2%	21%	193	+36.4%	33%	96.0	-42.8%	16%	566	-10.0%	96%
Venofer	90	-1.5%	30%	71	-20.7%	24%	116	+60.8%	39%	36	-65.0%	12%	314	-12.2%	104%
EUR Mn															
Daiichi Sankyo Europe GmbH	144	+13.6%	21%	153	+2.7%	23%	165	+2.5%	25%	182.0	+21.5%	27%	644	+9.8%	96%
Olmesartan	101	+23.1%	21%	110	+5.1%	23%	121	+1.3%	25%	136	+33.5%	29%	468	+14.7%	98%
Olmetec/Olmetec Plus	74	+9.4%	21%	80	-4.4%	23%	88	-2.0%	25%	95	+13.4%	27%	336	+3.7%	97%
Sevikar	21	+43.7%	20%	24	+11.5%	23%	25	+21.1%	24%	32	+75.2%	30%	101	+35.9%	97%
Sevikar HCT	6	-	24%	6	-	25%	8	-10.6%	31%	10	+1366.1%	39%	31	+218.7%	119%
Efient (alliance revenue)	5	-	-	6	-	-	7	-	-	10	-	-	27	-	-
INR Bn															
Ranbaxy Laboratories Limited	22	-21.5%	26%	21	-1.5%	25%	21	+8.0%	25%	38.0	+82.4%	45%	101	+13.9%	119%

5. Sales of Global Products (FY2011)

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn															
Olmesartan	63.3	+5.2%	24%	60.4	-1.6%	22%	64.2	-2.3%	24%	61.7	+13.9%	23%	249.7	+3.4%	93%
Olmetec (JPN)	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas (JPN)	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Benicar/Benicar HCT (US)	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor (US)	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor (US)	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Olmetec/Olmetec Plus (EU)	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar (EU)	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT (EU)	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Other subsidiaries, export, etc	3.3	+16.4%	20%	4.3	+10.4%	25%	4.4	+28.8%	26%	4.5	+18.3%	26%	16.5	+18.3%	97%
Levofloxacin	13.5	-20.2%	26%	12.8	-24.1%	24%	13.9	-23.3%	26%	12.2	-29.1%	23%	52.4	-24.2%	99%
Cravit (JPN)	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Other subsidiaries	2.0	-4.7%	25%	2.1	-4.9%	26%	1.9	-12.9%	23%	2.0	-11.9%	25%	7.9	-8.6%	99%
Pravastatin	10.2	-13.9%	27%	10.0	-15.5%	26%	10.6	-8.6%	28%	8.4	-12.6%	22%	39.2	-12.7%	103%
Mevalotin (JPN)	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Other subsidiaries, export, etc	1.5	-12.9%	25%	1.3	-22.1%	22%	1.7	+10.7%	29%	1.6	-15.1%	26%	6.1	-10.4%	102%
Prasugrel	2.2	+176.5%	-	2.3	+134.2%	-	2.6	+72.6%	-	3.8	+94.3%	-	10.9	+108.2%	-
Effient alliance revenue (US)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Effient alliance revenue (EU)	0.6	+34.9%	-	0.6	+165.9%	-	0.7	+65.5%	-	1.0	+47.9%	-	2.9	+64.8%	-

1. Summary of Consolidated Income Statement (FY2010)

JPY Bn	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	256.4	+12.9%	100%	242.5	-0.4%	100%	249.2	-2.3%	100%	219.3	-3.2%	100%	967.4	15.3	+1.6%
Cost of sales	25%	64.1	+2.5%	31%	74.4	-0.4%	30%	74.6	-1.1%	31%	68.6	+5.0%	29%	281.7	3.6	+1.3%
Gross Profit	75%	192.4	+16.9%	69%	168.0	-0.4%	70%	174.6	-2.8%	69%	150.7	-6.4%	71%	685.7	11.6	+1.7%
SG&A expenses	51%	131.3	-4.7%	57%	139.0	-3.9%	58%	144.1	+2.6%	68%	149.2	-4.1%	58%	563.5	-15.0	-2.6%
R&D expenses	17%	43.6	-3.4%	19%	45.7	-6.7%	21%	53.0	+11.4%	24%	52.0	-5.6%	20%	194.3	-2.5	-1.3%
Other expenses	34%	87.7	-5.4%	38%	93.3	-2.5%	37%	91.1	-2.0%	44%	97.2	-3.3%	38%	369.2	-12.5	-3.3%
Operating Income	24%	61.1	+128.1%	12%	29.0	+20.6%	12%	30.5	-22.2%	1%	1.5	-72.2%	13%	122.1	26.6	+27.9%
Non-operating income / expenses		9.0			-6.5			7.4			-0.4			9.6	2.0	
Non-operating income		11.8			-1.7			7.5			5.6			23.2	-5.0	
Non-operating expenses		2.8			4.8			0.0			6.0			13.6	-7.0	
Ordinary Income	27%	70.1	+877.7%	9%	22.6	-50.0%	15%	38.0	-1.1%	1%	1.2	-90.7%	14%	131.8	28.6	+27.8%
Extraordinary income / losses		-4.0			5.5			-1.2			-11.6			-11.3	-5.6	
Extraordinary income		0.8			6.8			0.9			4.3			12.8	6.9	
Extraordinary losses		4.8			1.3			2.2			15.9			24.2	12.5	
Income before income taxes and minority interests	26%	66.1	+665.1%	12%	28.0	-37.7%	15%	36.7	-1.6%	-5%	-10.4	-	12%	120.4	23.0	+23.7%
Income taxes / minority interests		33.0			9.0			9.2			-0.9			50.3	-5.2	
Income taxes		26.6			8.2			8.0			-0.9			41.8	-8.2	
Minority interests		6.5			0.8			1.2			0.0			8.5	3.0	
Net Income	13%	33.1	-	8%	19.1	-24.1%	11%	27.5	+33.8%	-4%	-9.5	-	7%	70.1	28.3	+67.5%
Effective tax rate		40%			29%			22%			-			35%		
Overseas sales ratio results		52%			51%			46%			53%			51%		

2. Currency Rate (FY2010)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2010
	Results	Results	Results	Results	Results YoY
USD/JPY (average)	92.02	88.95	86.53	85.72	85.72 -7.14
EUR/JPY (average)	117.00	113.84	113.31	113.13	113.13 -18.03
INR/JPY (average)	1.98	2.01	1.96	1.93	1.93 -0.02

3. Segment Information (FY2010)

Daiichi Sankyo Group	Q1			to sales	Q2			to sales	Q3			to sales	Q4			FY2010			
	to sales	Results	YoY		to sales	Results	YoY		to sales	Results	YoY		to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	201.6	+2.1%		100%	198.8	-4.0%		100%	213.7	-2.4%		100%	181.3	-0.3%	100%	795.5	-10.0	-1.2%
Cost of sales	22%	44.9	-1.1%		27%	54.4	+0.1%		26%	55.0	-1.1%		26%	47.6	+0.5%	25%	201.8	-0.8	-0.4%
Gross Profit	78%	156.7	+3.1%		73%	144.4	-5.4%		74%	158.8	-2.9%		74%	133.8	-0.6%	75%	593.7	-9.1	-1.5%
SG&A expenses	56%	113.5	-7.0%		61%	121.2	-4.2%		60%	127.7	+2.7%		73%	131.5	-2.5%	62%	493.9	-13.7	-2.7%
R&D expenses	20%	40.3	-6.2%		22%	43.5	-6.9%		24%	50.6	+12.0%		27%	49.6	-4.0%	23%	184.0	-2.5	-1.3%
Other expenses	36%	73.2	-7.4%		39%	77.7	-2.6%		36%	77.1	-2.6%		45%	81.9	-1.5%	39%	309.9	-11.2	-3.5%
Operating Income	22%	43.3	+44.0%		12%	23.2	-11.6%		15%	31.1	-20.6%		1%	2.3	-1422.3%	13%	99.8	4.6	+4.8%
Non-operating income		1.8				1.9				2.6				0.9			7.2	0.2	
Non-operating expenses		1.7				2.0				-0.1				3.4			7.0	0.9	
Ordinary Income	22%	43.4	+34.8%		12%	23.1	-12.6%		16%	33.7	-12.9%		0%	-0.2	-	13%	100.0	3.8	+4.0%
Extraordinary income		0.8				3.8				1.4				4.3			10.2	5.7	
Extraordinary losses		4.2				1.0				0.7				15.0			20.9	9.3	
Income before income taxes and minority interests	20%	40.0	+18.8%		13%	25.9	-1.6%		16%	34.4	-8.6%		-6%	-10.9	-	11%	89.3	0.2	+0.2%
Income taxes		17.7				7.5				8.5				-3.1			30.6	-23.7	
Minority interests																			
Net Income	11%	22.3	+122.8%		9%	18.3	+39.4%		12%	26.0	+30.0%		-4%	-7.8	-	7%	58.8	23.9	+68.6%
Ranbaxy Group																			
Net sales	100%	54.9	+84.9%		100%	43.8	+20.1%		100%	35.5	-1.4%		100%	38.9	-12.6%	100%	173.1	26.4	+18.0%
Cost of sales	35%	19.2	+12.0%		46%	20.0	-1.8%		55%	19.5	-1.7%		54%	21.0	+16.6%	46%	79.8	4.4	+5.8%
Gross Profit	65%	35.7	+184.1%		54%	23.7	+48.0%		45%	16.0	-1.1%		46%	17.9	-32.5%	54%	93.3	22.1	+31.0%
SG&A expenses	30%	16.4	+13.9%		39%	17.1	+2.9%		43%	15.4	+5.3%		43%	16.7	-13.5%	38%	65.6	0.7	+1.0%
R&D expenses	6%	3.3	+56.2%		7%	3.0	+32.0%		8%	2.8	+19.0%		7%	2.8	-19.0%	7%	12.0	1.7	+16.7%
Other expenses	24%	13.1	+6.7%		32%	14.1	-1.8%		35%	12.5	+2.6%		36%	13.9	-12.3%	31%	53.5	-1.1	-2.0%
Operating Income	35%	19.3	-1171.9%		15%	6.6	-1214.7%		2%	0.6	-60.0%		3%	1.1	-83.9%	16%	27.7	21.4	+338.8%
Non-operating income		10.0				-3.0				4.9				4.2			16.2	-5.0	
Non-operating expenses		1.1				2.7				0.1				0.1			3.9	-10.5	
Ordinary Income	52%	28.3	-220.1%		2%	0.9	-95.4%		16%	5.5	+374.9%		14%	5.3	-65.1%	23%	40.0	27.0	+207.8%
Extraordinary income		0.0				5.2				0.0				-0.1			5.1	3.8	
Extraordinary losses		0.7				0.1				1.5				6.0			8.3	8.2	
Income before income taxes and minority interests	50%	27.6	-217.5%		14%	6.0	-70.2%		11%	4.0	+249.7%		-2%	-0.8	-	21%	36.8	22.6	+158.6%
Income taxes		9.2				1.5				0.1				2.4			13.2	3.4	
Minority interests		0.1				0.1				0.1				0.1			0.3	0.1	
Net Income	33%	18.4	-		10%	4.5	-68.3%		11%	3.8	-		-9%	-3.3	-	14%	23.3	19.1	+456.4%
Inter-segment Transactions																			
Net sales		-0.1				-0.1				-0.1				-0.9			-1.2		
Cost of sales		0.0				0.0				0.1				0.0			0.1		
Gross Profit		-0.1				-0.1				-0.2				-0.9			-1.3		
SG&A expenses		1.5				0.7				1.0				1.0			4.1		
R&D expenses		0.0				-0.8				-0.4				-0.4			-1.7		
Other expenses		1.5				1.5				1.4				1.4			5.8		
Operating Income		-1.5				-0.7				-1.2				-1.9			-5.4		
Non-operating income		0.0				-0.7				-0.1				0.5			-0.2		
Non-operating expenses						0.1				0.0				2.5			2.6		
Ordinary Income		-1.5				-1.5				-1.3				-3.9			-8.2		
Extraordinary income		0.0				-2.2				-0.5				0.1			-2.5		
Extraordinary losses						0.2				0.0				-5.2			-5.0		
Income before income taxes and minority interests		-1.5				-3.9				-1.7				1.4			-5.7		
Income taxes		-0.3				-0.8				-0.6				-0.2			-2.0		
Minority interests		6.4				0.7				1.1				-0.1			8.2		
Net Income		-7.6				-3.8				-2.2				1.6			-12.0		

4. Sales by Business Units (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Consolidated Net Sales	256.4	+12.9%	242.5	-0.4%	249.2	-2.3%	219.3	-3.2%	967.4	+1.6%
Japan Company (domestic sales)	105.3	+0.6%	103.0	-1.7%	116.8	-1.4%	91.0	+7.6%	416.0	+0.9%
Olmotec	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Calblock	3.7	+6.5%	3.5	+0.6%	3.8	-0.6%	2.9	+1.3%	14.0	+1.9%
Loxonin	13.0	+15.9%	13.9	+11.0%	14.7	+10.0%	12.6	+27.3%	54.2	+15.3%
Cravit	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Mevalotin	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Artist	6.1	+1.8%	5.8	-1.6%	6.3	-0.9%	5.4	+8.5%	23.7	+1.6%
Omnipaque	6.4	-10.1%	6.6	-12.4%	6.5	-8.5%	5.4	-0.2%	25.0	-8.3%
Urief	2.5	+11.2%	2.5	+9.2%	2.8	+9.2%	2.3	+16.5%	10.1	+11.3%
Inavir	-	-	-	-	2.8	-	3.9	-	6.6	-
Vaccines	1.7	+36.2%	4.6	+139.8%	8.5	-1.2%	2.9	+128.3%	17.8	+35.6%
Daiichi Sankyo Espha products	-	-	-	-	2.6	-	2.0	-	4.6	-
Daiichi Sankyo Healthcare (OTC)	9.3	-2.7%	11.7	-12.9%	13.2	+9.1%	10.6	+23.2%	44.8	+2.6%
Daiichi Sankyo, Inc. (US)	33.6	+1.7%	33.9	+1.2%	34.6	+0.6%	28.4	-11.6%	130.5	-1.9%
Olmesartan	25.2	+0.6%	24.7	-2.5%	24.6	-6.9%	19.9	-19.8%	94.5	-7.1%
Benicar/Benicar HCT	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor	-	-	0.7	-	0.5	-	0.3	-	1.5	-
Welchol	7.0	+1.8%	7.4	+13.4%	7.9	+7.6%	6.3	-8.3%	28.5	+3.6%
Effient (alliance revenue)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Luitpold Pharmaceuticals, Inc. (US)	14.7	+10.4%	13.7	+1.3%	11.5	-8.5%	14.0	+10.5%	53.9	+3.5%
Venofer	8.4	+5.2%	7.7	-5.0%	5.8	-27.1%	8.7	+8.4%	30.7	-4.6%
Daiichi Sankyo Europe GmbH	14.8	-14.6%	16.6	-10.0%	18.1	-5.0%	16.9	-17.2%	66.4	-11.7%
Olmesartan	9.6	+4.5%	11.7	+4.5%	13.4	+7.9%	11.5	-14.7%	46.2	-0.2%
Olmotec/Olmotec Plus	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT	-	-	-	-	1.0	-	0.1	-	1.1	-
Asia, South and Central America (ASCA)	5.9	+12.7%	7.1	+12.8%	6.8	+3.3%	7.6	-0.4%	27.4	+6.4%
Daiichi Sankyo Pharmaceutical (Beijing)	1.1	+17.8%	1.1	+3.6%	1.1	-6.3%	0.9	-2.2%	4.2	+2.9%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.4	+35.5%	1.7	+32.5%	1.6	+10.5%	1.8	+20.7%	6.6	+23.8%
Daiichi Sankyo Taiwan	0.8	-8.6%	0.8	+1.0%	0.8	+13.5%	1.0	+29.2%	3.4	+7.9%
Daiichi Sankyo Korea	1.0	+31.4%	0.9	+2.9%	1.0	+9.7%	1.1	+29.6%	4.0	+17.9%
Daiichi Sankyo (Thailand)	0.2	+35.8%	0.3	+22.8%	0.3	+53.4%	0.3	+26.9%	1.2	+33.8%
Daiichi Sankyo Brasil Farmacêutica	1.0	+36.5%	1.4	+39.5%	1.4	+6.4%	1.3	-19.9%	5.2	+9.5%
Daiichi Sankyo Venezuela	0.4	-46.7%	0.7	-18.7%	0.6	-25.1%	1.1	-32.7%	2.9	-30.5%
Ranbaxy Laboratories Limited	54.8	+84.7%	43.7	+19.9%	35.4	-1.6%	38.0	-14.5%	171.9	+17.3%
Others	18.0	+25.6%	12.8	-25.1%	12.7	-20.2%	12.8	-20.0%	56.3	-11.1%
Levofloxacin export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Efient alliance revenue (Europe)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

[Reference] Sales in Local Currency (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
Daiichi Sankyo, Inc. (US)	365	+7.6%	394	+10.2%	422	+10.3%	342	-3.3%	1,522	+6.3%
Olmesartan	274	+6.4%	287	+6.2%	300	+2.3%	241	-12.2%	1,102	+0.6%
Benicar/Benicar HCT	233	+2.7%	241	+1.6%	251	-0.5%	205	-15.2%	930	-2.9%
Azor	42	+33.1%	39	+16.9%	42	+4.6%	32	-1.0%	155	+12.7%
Tribenzor	-	-	7	-	6	-	4	-	17	-
Welchol	76	+7.6%	85	+23.1%	95	+17.8%	76	+0.3%	333	+12.2%
Effient (alliance revenue)	4	-	9	-	13	-	15	-	40	-
USD Mn										
Luitpold Pharmaceuticals, Inc. (US)	160	+16.7%	159	+10.6%	142	+1.2%	168	+20.1%	629	+12.1%
Venofer	92	+11.3%	90	+3.8%	72	-18.5%	104	+17.5%	358	+3.4%
EUR Mn										
Daiichi Sankyo Europe GmbH	126	-3.2%	149	+8.3%	161	+12.1%	150	-7.0%	587	+2.3%
Olmesartan	82	+18.4%	105	+25.4%	119	+27.3%	102	-3.9%	408	+15.7%
Olmetec/Olmetec Plus	68	+8.5%	83	+12.0%	90	+16.1%	83	-7.6%	324	+6.5%
Sevikar	14	+109.5%	21	+136.0%	20	+24.9%	18	+12.8%	74	+53.6%
Sevikar HCT	-	-	-	-	9	-	1	-	10	-
INR Bn										
Ranbaxy Laboratories Limited	28	+76.3%	21	+17.1%	19	+4.6%	21	-9.0%	89	+18.5%

5. Sales of Global Products (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Olmesartan	60.2	+7.6%	61.4	+3.4%	65.7	+1.6%	54.2	-7.0%	241.5	+1.4%
Olmetec (JPN)	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas (JPN)	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Benicar/Benicar HCT (US)	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor (US)	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor (US)	-	-	-	-	0.5	-	0.3	-	1.5	-
Olmetec/Olmetec Plus (EU)	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar (EU)	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT (EU)	-	-	-	-	1.0	-	0.1	-	1.1	-
Other subsidiaries, export, etc	2.8	+7.7%	3.9	+25.4%	3.5	-6.2%	3.8	+0.8%	13.9	+6.0%
Levofloxacin	17.0	-14.3%	16.9	-28.0%	18.1	-18.3%	17.2	-21.1%	69.1	-20.7%
Cravit (JPN)	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Other subsidiaries	2.1	+15.8%	2.2	+10.6%	2.1	+2.0%	2.2	+25.6%	8.7	+12.9%
Pravastatin	11.9	-19.1%	11.8	-21.5%	11.6	-21.8%	9.6	-8.3%	44.9	-18.4%
Mevalotin (JPN)	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Other subsidiaries, export, etc	1.7	-25.8%	1.7	-34.1%	1.6	-20.9%	1.8	-6.1%	6.8	-22.8%
Prasugrel (alliance revenue)	0.8	-	1.0	-	1.5	-	2.0	-	5.2	+889.6%
Effient alliance revenue (US)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Efient alliance revenue (EU)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%